

# UCSF

## UC San Francisco Previously Published Works

### Title

A Compendium of Promoter-Centered Long-Range Chromatin Interactions in the Human Genome

### Permalink

<https://escholarship.org/uc/item/9ng2w70x>

### Author

Chan, Marilyn

### Publication Date

2019-10-01

### Data Availability

The data associated with this publication are available at:

<https://www.ncbi.nlm.nih.gov/geo/>

Peer reviewed

**1Title:**

**2A Compendium of Promoter-Centered Long-Range  
3Chromatin Interactions in the Human Genome**

**4Authors:**

5Inkyung Jung<sup>1\*†</sup>, Anthony Schmitt<sup>2,3\*</sup>, Yarui Diao<sup>2,4\*</sup>, Andrew J. Lee<sup>1</sup>, Tristin  
6Liu<sup>2</sup>, Dongchan Yang<sup>5</sup>, Catherine Tan<sup>2</sup>, Junghyun Eom<sup>1</sup>, Marilyn Chan<sup>6</sup>,  
7Sora Chee<sup>2</sup>, Zachary Chiang<sup>7</sup>, Changyoun Kim<sup>8,9</sup>, Eliezer Masliah<sup>8,9,10</sup>, Cathy  
8L. Barr<sup>11</sup>, Bin Li<sup>1</sup>, Samantha Kuan<sup>2</sup>, Dongsup Kim<sup>5</sup>, Bing Ren<sup>2,12†</sup>

9

**10Affiliations:**

11<sup>1</sup>Department of Biological Sciences, KAIST, Daejeon 34141, Korea

12<sup>2</sup>Ludwig Institute for Cancer Research, La Jolla, CA 92093, USA

13<sup>3</sup>UCSD Biomedical Sciences Graduate Program, La Jolla, CA 92093, USA

14<sup>4</sup>Departments of Cell Biology and Orthopaedic Surgery, Regenerative Next  
15Initiative, Duke University School of Medicine. Durham, NC 27710

16<sup>5</sup>Department of Bio and Brain engineering, KAIST, Daejeon 34141, Korea

17<sup>6</sup>University of California San Francisco, San Francisco, CA 94158, USA

18<sup>7</sup>Department of Bioengineering, UCSD, La Jolla, CA 92093, USA

19<sup>8</sup>Molecular Neuropathology Section, Laboratory of Neurogenetics, National  
20Institute on Aging, National Institutes of Health, Bethesda, MD 20892, USA

21<sup>9</sup>Department Neurosciences, School of Medicine, University of California,

22San Diego, La Jolla, CA 92093, USA

23<sup>10</sup>Department of Pathology, School of Medicine, University of California,  
24San Diego, La Jolla, CA 92093, USA

25<sup>11</sup>Krembil Research Institute, University Health Network, Toronto, and The  
26Hospital for Sick Children, Ontario M5T 2S8, Canada

27<sup>12</sup>Department of Cellular and Molecular Medicine, Institute of Genomic  
28Medicine, and Moores Cancer Center, University of California at San Diego,  
29La Jolla, CA 92093, USA

30

31\*These authors contributed equally to this work

32<sup>†</sup>Correspondence to Inkyung Jung ([ijung@kaist.ac.kr](mailto:ijung@kaist.ac.kr)) and Bing Ren  
33([biren@ucsd.edu](mailto:biren@ucsd.edu))

34

35Note:

36All raw and processed data are deposited into GEO database under  
37accession number GSE86189. Reviewer's access token is  
38mtsxkwgunlipvqb.

39A genome browser session has been set up for visualization of the  
40promoter-centered chromatin interactions described in the current study -

41<http://epigenomegateway.wustl.edu/browser/?>

42[genome=hg19&session=IR82F6oIpo&statusId=446157315](http://epigenomegateway.wustl.edu/browser/?genome=hg19&session=IR82F6oIpo&statusId=446157315) (Remy the  
43chef)

44

45

46

47

48

49

50**Abstract:**

51**A large number of putative *cis*-regulatory sequences have been**  
52**annotated in the human genome, but the genes they control**  
53**remain to be defined. To bridge this gap, we generate maps of**  
54**long-range chromatin interactions centered on 18,943 well-**  
55**annotated promoters for protein-coding genes in 27 human**  
56**cell/tissue types. We use this information to infer the target**  
57**genes of 70,329 candidate regulatory elements, and suggest**  
58**potential regulatory function for 27,325 non-coding sequence**  
59**variants associated with 2,117 physiological traits and diseases.**  
60**Integrative analysis of these promoter-centered interactome**  
61**maps reveals widespread enhancer-like promoters involved in**  
62**gene regulation and common molecular pathways underlying**  
63**distinct groups of human traits and diseases.**

64

65**Main Text:**

66Genome-Wide Association Studies (GWAS) have uncovered thousands of  
67genetic variants associated with human diseases and phenotypic traits<sup>1</sup>,  
68but molecular characterization of these genetic variants has been  
69challenging because they are mostly non-coding and lack clear functional  
70annotation. Recent studies have shown that these non-coding variants are  
71frequently marked by chromatin signatures of *cis*-regulatory elements  
72(cREs) in cells, leading to the hypothesis that a substantial fraction of  
73variants may act by affecting transcriptional regulation<sup>2,3</sup>. To formally test

74this hypothesis, it is critical to define the target genes of cREs in the  
75human genome. However, inferring target genes of cREs based on linear  
76genomic sequences is not straightforward, since cREs can regulate non-  
77adjacent genes over large genomic distances<sup>4-7</sup>. Such long-range  
78regulation can take place because chromatin fibers are folded into a  
79higher-order structure in which distant DNA fragments can be juxtaposed  
80in space<sup>8</sup>. Consequently, mapping spatial contacts between DNA has the  
81potential to uncover target genes of cREs. To this end, Chromosome  
82Conformation Capture (3C) techniques such as 4C-seq, ChIA-PET and Hi-C  
83have been developed to determine chromatin interactions in a high  
84throughput manner<sup>9-15</sup>. More recently, Hi-C combined with targeted  
85capture and sequencing (capture Hi-C) has emerged as a cost-effective  
86method to map chromatin interactions for specific regions at high-  
87resolution<sup>16-25</sup>.

88

89In order to systematically annotate candidate target genes for the cREs in  
90the human genome, we performed capture Hi-C experiments (Fig. 1a;  
91Extended Data Fig. 1) to interrogate chromatin interactions centered at  
92well-annotated human gene promoters for 19,462 protein-coding genes  
93(see Methods). We carried out these experiments with 27 human  
94cell/tissue types including embryonic stem cells, four early embryonic  
95lineages (mesendoderm, mesenchymal stem cell, neural progenitor cells,  
96and trophoblast), two primary cell lines (fibroblast cells and  
97lymphoblastoid cells), and 20 primary tissue types (hippocampus,

98dorsolateral prefrontal cortex, esophagus, lung, liver, pancreas, small  
99bowel, sigmoid colon, thymus, bladder, adrenal gland, aorta, gastric  
100tissue, left heart ventricle, right heart ventricle, right heart atrium, ovary,  
101psoas, spleen, and fat) for which reference epigenome maps have  
102previously been produced as part of the Epigenome Roadmap project  
103(Extended Data Fig. 2a; Supplementary Table 1)<sup>26</sup>. We designed and  
104synthesized 12 capture probes for each promoter, six for each of the  
105nearest *HindIII* restriction sites upstream and downstream of the  
106transcription start site (TSS). Among 16,720 promoter-containing *HindIII*  
107restriction DNA fragments, 14,357 (86%) contain a single promoter, but  
108the 2,363 remaining *HindIII* fragments harbor multiple promoters  
109(Extended Data Fig. 2b; see Methods). The robustness and the coverage  
110of capture probe synthesis were validated by sequencing (Extended Data  
111Fig. 2c-f). On average, each capture Hi-C experiment produced 65 million  
112unique, on-target paired-end reads, yielding a total of 1.8 billion valid read  
113pairs, ~30% of which were between DNA fragments >15kb apart  
114(Supplementary Table 2).

115

116To identify the long-range chromatin interactions from the capture Hi-C  
117data, two normalization steps were introduced. First, the biases in capture  
118efficiency of each promoter (Extended Data Fig. 2g, h) were calibrated  
119with the variable “capturability” for each DNA fragment, defined as the  
120fraction of total read counts mapped to the region, using a  $\beta$ -spline  
121regression model (see Methods). Second, significant chromatin

122interactions were then identified after normalizing against the distance-  
123dependent background signals (9% and 5% FDR for P-O and P-P  
124interactions, respectively) (see Methods). Focusing on the *HindIII*  
125fragments over 15kb away and within 2Mbp of each promoter, we  
126determined a total of 892,013 chromatin interactions (431,141 unique  
127interacting pairs) in one or more of the 27 human cell/tissue types (Fig.  
1281b; Extended Data Fig. 3a; Supplementary Table 3-5). The median  
129distance between the interacting DNA pairs was 158kb, which is within a  
130similar range of previously reported chromatin loops and eQTL  
131associations (Fig. 1c; Supplementary Table 6)<sup>10,12,13</sup>. The slight discrepancy  
132between pHi-C interactions and eQTL-associations may be attributed to  
133different experimental approaches, but nevertheless, the two methods  
134give complementary information to each other. Between 13% and 45%  
135pHi-C interactions detected in a cell or tissue type were unique to that  
136cell/tissue type (Extended Data Fig. 3b). As expected, most of the  
137detected chromatin interactions were within Topologically Associating  
138Domains (TADs) defined in the corresponding tissue/cell type (Extended  
139Data Fig. 3c, d)<sup>27,11</sup>.

140

141To demonstrate that pHi-C could effectively and reproducibly capture  
142long-range chromatin interactions as detected by whole genome *in situ*  
143Hi-C, we compared the pHi-C data with the *in situ* Hi-C data obtained  
144from four distinct biosamples, including two cell lines (IMR90 lung  
145fibroblast cell line and GM12878 lymphoblastoid cell line<sup>13</sup>) and two

146primary tissues - dorsolateral prefrontal cortex and hippocampus (see  
147Methods). Results of pHi-C experiments accurately recapitulated  
148chromatin loops identified from *in situ* Hi-C assays in all samples, with the  
149area under the receiver operating curve (ROC) ranging between 0.84 and  
1500.91 (Extended Data Fig. 4a-e) (see Methods). Additionally, we found high  
151reproducibility of pHi-C chromatin interactions between different donors  
152(average ROC score = 0.85; the average Spearman's rank correlation  
153between replicates = 0.4; Extended Data Fig. 4f-j; Supplementary Table 7;  
154see Methods), and between two independent studies (Extended Data Fig.  
1554k). The observation that interactions identified in both replicates  
156exhibited the strongest interaction signals, while interactions identified in  
157one replicate were moderately strong in one replicate, but moderately  
158weak in the other replicate (Extended Data Fig. 4l-m), suggests that the  
159interactions that are specific to one replicate may be due to under-  
160sampling of the other replicate.

161

162The chromatin interactome maps allowed us to assign candidate target  
163genes for 70,329 putative cREs, defined based on histone H3K27ac  
164signals in each tissue/cell type profiled previously<sup>26</sup>, for 17,295 promoters.  
165Each promoter was putatively assigned to 25 cREs on average (Extended  
166Data Fig. 5a), while 45% of cREs were assigned to one candidate target  
167gene (Extended Data Fig. 5b), similar to the previous observation with  
168DNase I hypersensitivity analysis across diverse human cell types<sup>28</sup>. We  
169took advantage of the existing chromatin datasets collected for the same

170 tissue/cell types<sup>26</sup>, and examined the relationship of the chromatin states  
171 between the cREs and the target promoters (see Methods). As expected,  
172 the fragments that extensively interact with multiple promoters were  
173 often found at active chromatin regions, such as TF binding clusters or  
174 super enhancer regions (Extended Data Fig. 5c-i; Supplementary Table 8-  
175 10; see Methods)<sup>29</sup>. Furthermore, integrative analysis with ChromHMM  
176 model revealed that active promoters interact three times more  
177 frequently with DNA fragments harboring active enhancers than the  
178 bivalent promoters (Fig. 1d). On the other hand, the bivalent promoters  
179 interact five times more frequently with genomic regions associated with  
180 Polycomb Repressor Complexes than the active promoters (Fig. 1d).  
181 Further analysis based on a refined 50-chromatin-state ChromHMM model  
182 for 5 cell lines also supports our conclusion (Extended Data Fig. 6).

183

184 Three lines of evidence demonstrate that the above promoter-centered  
185 chromatin interactions contain information on regulatory interactions at  
186 each promoter in the corresponding cell/tissue types. First, we compared  
187 the chromatin interactions at promoters with regulatory relationships  
188 inferred from expression quantitative trait loci (eQTL) in 14 matched  
189 tissue-types that were recently reported by the GTEx consortium (see  
190 Methods) (Fig. 2a; Extended Data Fig. 7a-c)<sup>30</sup>. For each tissue and cell  
191 type, the previously reported eQTLs were highly enriched in the chromatin  
192 interactions identified in the corresponding tissue, with enrichment up to  
193 five-fold (ovary) (Fig. 2b; Extended Data Fig. 7d and e). A total of 42,627

194eQTL associations were detected by pHi-C chromatin interactions, while  
195only 21,362 were expected by random chance after controlling for linear  
196genomic distances (Supplementary Table 11 and 12). Second, there is  
197significant correlation between activities of *cis*-regulatory sequences and  
198the assigned candidate target gene expression across multiple tissues and  
199cell types, consistent with the purported regulatory relationships.  
200Specifically, the histone modification status of H3K27ac of these cREs was  
201significantly correlated with the promoter H3K27ac levels (KS-test P value  
202< 2.2e-16; Extended Data Fig. 7f) and transcription levels of the predicted  
203target genes (KS-test P value < 2.2e-16; Extended Data Fig. 7g) across  
204these tissues/cell types. For example, the *POU3F3* gene expression  
205(second column in Fig. 2c) was highly correlated with H3K27ac signals in  
206the distal cRE (first column in Fig. 2c) connected by a tissue-specific  
207chromatin interaction (last column in Fig. 2c). Lastly, cell/tissue-specific  
208cRE-promoter pairs connected by pHi-C interactions are significantly  
209associated with active cREs and genes that are specific to the same  
210cell/tissue types. For example, hippocampus specific cRE-promoter  
211chromatin interactions are significantly associated with active cREs (Fig.  
2122d) and highly expressed genes, albeit modest, (Fig. 2e) in hippocampus.  
213Significant associations of cell/tissue-specific pHi-C interactions in active  
214cREs and highly expressed genes are found in other cell/tissue types as  
215well (Fig. 2f-h, KS-test P value < 2.2e-16, see Methods). The above results,  
216taken together, strongly suggest that the predicted cRE-promoter pairs

217could uncover regulatory relationships between the cRE and target genes  
218in diverse tissues and cell types.

219

220Widespread promoter-promoter (P-P) interactions have been reported in  
221cultured mammalian cells and a few primary tissues<sup>14,21,31</sup>. The promoter-  
222centered interaction maps obtained from 27 diverse tissues and cell types  
223allowed us to test whether this is a general phenomenon. Indeed,  
224consistent with previous reports, a significant fraction of the chromatin  
225interactions was found between two promoters (9%,  $n = 79,989$ , Fisher's  
226Exact test  $p$  value  $< 2.2e-16$ , Extended Data Fig. 8a). The physical  
227proximity of these promoters is accompanied by a strikingly high  
228correlation in chromatin modification state between the pair of promoters  
229across diverse cell/tissue types (Fig. 3a, b). Previously, several promoter  
230loci have been shown to function as enhancers to regulate distal genes<sup>32-</sup>  
231<sup>34</sup>. In support of the functional significance of enhancer-like promoters  
232identified in the current study, 6,127 eQTLs match P-P interaction pairs,  
233while only 2,722 eQTLs were expected by random chance (Fig. 3c;  
234Extended Data Fig. 8b-d; Supplementary Table 13 and 14; see Methods).  
235For instance, strong chromatin interactions were found between the  
236*DACT3* and *AP2S1* gene promoter regions, and one significant eQTL  
237(rs78730097) for *DACT3* gene was located in the *AP2S1* promoter in the  
238dorsolateral prefrontal cortex (Fig. 3d). Notably, this eQTL does not show  
239any meaningful genetic association with the adjacent downstream gene  
240(*AP2S1*) or nearby genes, but is exclusively associated with *DACT3*

241(Extended Data Fig. 8e), suggesting regulatory potential of the *AP2S1*  
242promoter region in distal *DACT3* gene regulation. To validate the function  
243of enhancer-like promoters, we deleted 2 core promoter regions, where  
244the downstream gene is not expressed but the promoter region shows  
245active chromatin marks, using CRISPR-mediated system (Extended Data  
246Fig. 8f, g; see Methods). Deletion of the *ARIH2OS* core promoter resulted  
247in marked down-regulation of the distal target gene (FDR adjusted p-value  
248= 0.02), *NCKIPSD*, identified by long-range chromatin interactions (Fig. 3e)  
249with no significant or moderate effect on nearby genes (Extended Data  
250Fig. 8h). Importantly, sgRNA-induced mutations in selected eQTLs  
251proximal to transcriptional start sites demonstrated significant down-  
252regulation effect on distal target genes but no significant effect on nearby  
253gene expression in H1-hESC (Fig. 3f; Extended Data Fig. 8i; see Methods).  
254Our results strongly suggest genome-wide presence of enhancer-like  
255promoters in the human genome and provide additional insight into their  
256potential function in distal gene regulation.

257

258The above promoter-centered chromatin interaction maps allowed us to  
259infer the target genes of sequences harboring disease-associated variants  
260and understand the molecular basis of human disease. We focused on  
26142,633 putative disease/trait-associated genetic variants from a recent  
262public repository of GWAS catalog<sup>1</sup>. Consistent with previous reports<sup>2,35</sup>, a  
263significant portion of SNPs (30%, Fisher's Exact test p value < 2.2e-16)  
264were found in putative cREs, emphasizing the importance of target gene

265identification of cREs in functional interpretation of disease associated  
266genetic variants. Since the causal SNPs are unknown in most cases, we  
267also included SNPs that lie outside the previously defined cREs for further  
268analysis. In total, we were able to assign target genes for 27,325 SNPs in  
269the list. On average, each SNP was assigned to between 1 and 3  
270candidate target genes in each cell/tissue type, with the caveat that the  
271precise number of target genes could potentially be affected by the  
272modest resolution of our promoter capture strategy and the heterogeneity  
273of tissue samples (Extended Data Fig. 9a; Supplementary Table 15; see  
274Methods). The above maps therefore provided many more predictions of  
275disease-associated genes than using the nearest neighbor gene  
276predictions alone (one example is provided for the Parkinson disease in  
277Extended Data Fig. 9b, c), with only about 8% of the putative target genes  
278inferred from our promoter-centered chromatin interaction maps were  
279found to be the closest gene to the sequence variant (Extended Data Fig.  
2809d). To evaluate the validity of target predictions based on the promoter-  
281centered chromatin interaction maps, we focused on 7 GWAS variants  
282that overlap with previously annotated cREs and eQTLs in human  
283lymphoblastoid cell line GM12878 cells. We introduced deletions to these  
284elements in GM12878 using CRISPR-Cas9 genome editing tools and  
285examined the expression of predicted target genes using RT-qPCR in the  
286mutant cells and controls. For 5 of the 7 tested cREs, genetic perturbation  
287led to down regulation of the predicted distal target genes (Fig. 4a and

288Extended Data Fig. 9e-f). This result supports the target gene predictions  
289based on the pHi-C interactions.

290

291Many diseases and traits could be linked to common molecular pathways,  
292and the identification of these shared molecular pathways can be  
293beneficial in understanding disease pathogenesis and developing  
294treatment. To uncover the common molecular pathways underlying  
295different diseases and physiological traits, we first determined the  
296diseases/traits that share a significant number of common target genes  
297predicted from their respective GWAS-associated SNPs. We grouped 687  
298traits and diseases into 40 clusters (Fig. 4b; Extended Data Fig. 10a-c;  
299Supplementary Table 16; see Methods). Many physiological traits with  
300known connections are found to be clustered together. For examples, C5  
301clusters oxygen transport related traits together, C6 groups together traits  
302related to renal functions, and C20 includes vascular function associated  
303traits (Fig. 4b). The above grouping is made possible thanks to the  
304promoter-centered chromatin interactome maps, because the similarities  
305among related traits observed in Fig. 4b were much less evident when we  
306used either GWAS SNPs or nearest genes of the GWAS SNPs to compute  
307the similarities as control experiments (Fig. 4c, d, Extended Data Fig.  
30810d). Our result suggests the power of target gene identification of GWAS  
309variants to uncover trait-trait associations.

310

311To further understand the common molecular pathways affected in  
312various human diseases, we carried out gene ontology (GO) analysis for  
313the predicted target genes of the GWAS SNPs within each cluster  
314(Supplementary Table 17; see Methods). The enriched GO biological  
315processes suggest potential shared molecular pathways for disease and  
316trait types in each cluster (Fig. 4e, Extended Data Fig. 10e,  
317Supplementary Table 18), including unexpected connections between  
318specific traits. For example, C39 exposes a link between the susceptibility  
319to infectious and autoimmune diseases and the risk of chemotherapeutic  
320toxicity by carboplatin and cisplatin. In support of such link, a putative  
321target gene associated with the response to carboplatin and cisplatin is  
322*ABCF1*, which is involved in inflammatory response<sup>36</sup>. While speculative,  
323the shared molecular pathways uncovered by our analyses may provide  
324new leads for investigation of the molecular basis of complex traits and  
325disease phenotypes.

326

327In summary, we have generated promoter-centered chromatin  
328interactome maps across diverse human cell/tissue types. Our analysis  
329covers a broad range of human tissue types and provides prediction of  
330target genes for over 70,000 putative *cis*-regulatory elements and 27,000  
331GWAS SNP variants. This resource enables a new approach to  
332understanding the molecular pathways dysregulated in distinct diseases  
333and traits<sup>21</sup>. In future studies, delineation of disease-specific chromatin  
334interactions with clinical samples by comparing our reference chromatin

335interaction maps could greatly improve the functional interpretation of  
336many disease and trait associated genetic variants.

337

338It should be noted that the current study only surveys a limited number of  
339human tissues and cell types, and assigned target genes for a small  
340fraction of the putative *cis*-regulatory elements annotated in the human  
341genome. Furthermore, the heterogeneous nature of the tissue samples  
342used in this study prevents us from accessing the cell types in which the  
343identified chromatin interactions occur, except for a few cell lines.

344Nevertheless, this resource lays the ground for further understanding of  
345human disease pathogenesis and development of new treatment  
346strategies.

347

348

## 349**Methods**

### 350**Human tissue samples**

351Esophagus, lung, liver, pancreas, small bowel, sigmoid colon, thymus,  
352bladder, adrenal gland, aorta, gastric, left heart ventricle, right heart  
353ventricle, right heart atrium, ovary, psoas, spleen, and fat tissues were  
354obtained from deceased donors at the time of organ procurement at  
355Barnes-Jewish Hospital (St. Louis, USA) as described in our previous  
356study<sup>26</sup>. The same tissue types from different donors were combined  
357together during downstream data analysis. Human dorsolateral prefrontal  
358cortex (DLPFC rep1) and hippocampus (HC rep1) tissues were obtained  
359from the National Institute of Child Health and Human Development  
360(NICHHD) Brain Bank for Developmental Disorders. These two samples were  
361from a healthy 31-year-old male donor. Ethics approval was obtained from  
362the University Health Network and The Hospital for Sick Children for the  
363use of these tissues. Another set of human dorsolateral prefrontal cortex  
364(DLPFC rep2) and hippocampus (HC rep2) tissues were obtained from the  
365Shiley-Marcos Alzheimer's Disease Research Center (ADRC). These two  
366samples were from a healthy 80-year-old female donor. Institutional  
367Review Board (IRB) approval was obtained from KAIST for the use of these  
368tissues.

369

### 370**Hi-C library on human tissue samples and early embryonic cell**

### 371**types**

372 Human tissue samples were flash frozen and pulverized prior to  
373 formaldehyde cross-linking. Fibroblasts (IMR90) and lymphoblastoid cell  
374 lines (GM12878 and GM19240) were cultured and 5 million cells were  
375 formaldehyde cross-linked for each Hi-C library. Hi-C was then conducted  
376 on the samples as previously described, using *HindIII* for Hi-C library  
377 preparation<sup>37</sup>. Previously constructed Hi-C libraries<sup>11</sup> were used for human  
378 ES cells (H1) and early embryonic cell types including mesendoderm,  
379 mesenchymal stem cell, neural progenitor cells, and trophoblast-like cells.  
380

### 381 **Generation of capture RNA probes**

382 In order to perform Promoter Capture Hi-C, we computationally designed  
383 RNA probes that capture promoter regions of previously annotated human  
384 protein coding genes. Capture regions were selected for 19,462 well-  
385 annotated protein coding gene promoters across 22 autosomes and X  
386 chromosome according to GENCODE v19 annotation with confidence level  
387 1 and 2. The annotation confidence level 1 and 2 comprise of genes that  
388 are accurately annotated with sufficient validation and manual annotation  
389 by combining the manual gene annotation from the Human and  
390 Vertebrate Analysis and Annotation (HAVANA) group, automatic gene  
391 annotation from Ensembl, and validating by CAGE. Due to the variability  
392 of capture efficiency, 19,328 promoter regions (99%) were captured in  
393 this study. Among them, 18,943 promoter regions were involved in pHi-C  
394 interactions in one or more cell/tissue types analyzed in this study. For  
395 each transcription start site, the two nearest left hand- and right hand-

396side *HindIII* restriction sites were selected. Six capture oligos were  
397designed to be of 120 nucleotide (nt) length and to have 30nt tiling  
398overhang. Oligos were designed +/- 300bp upstream and downstream of  
399each restriction site. As two restriction sites were chosen for each  
400transcription start site, a total of 12 capture oligos were designed to  
401target each promoter region. Capture sequences that overlap with directly  
402adjacent *HindIII* restriction sites were removed. GC contents of 94%  
403capture sequences ranged from 25% to 65%. Some promoters shared the  
404same *HindIII* fragment with at least one other, while 14,357 *HindIII*  
405fragments (86%) were uniquely assigned to one promoter. The effect of  
406the DNA fragments harboring multiple promoters on the quality of our  
407analytical findings is modest because only 15% of pHi-C interactions  
408emanated from the promoter sharing DNA fragments, and eliminating  
409these fragments results in no significant changes in our conclusion for  
410both eQTL enrichment test and gene set enrichment analysis. Further,  
411strong correlation of GWAS trait associations remains even after excluding  
412unresolvable promoters. In total, our capture oligo design generated  
413280,445 unique probe sequences including randomly selected capture  
414regions (i.e. gene deserts). Single-stranded DNA oligos were then  
415synthesized by CustomArray Inc. Single-stranded DNA oligos contained  
416universal forward and reverse primer sequences (total length 31nt),  
417whereby the forward priming sequence contained a truncated SP6  
418recognition sequence that was completed by the overhanging forward  
419primer during PCR amplification of the oligos. After PCR, double-stranded

420DNA was converted into biotinylated RNA probes through *in vitro*  
421transcription with the SP6 Megascript kit and in the presence of a  
422biotinylated UTP, as previously described<sup>11</sup>.

423

#### 424**Promoter Capture Hi-C library construction**

425Promoter Capture Hi-C library was constructed by performing target  
426enrichment protocol (enriching target promoter-centered proximity  
427ligation fragments from Hi-C library using capture RNA probes). Briefly, we  
428incubated 500ng Hi-C library for 24h at 65°C in a humidified hybridization  
429chamber with 2.5ug human Cot-1 DNA (Life Technologies), 2.5ug salmon  
430sperm DNA (Life Technologies), and p5/p7 blocking oligos with  
431hybridization buffer mix (10X SSPE, 10mM EDTA, 10X Denhardt's solution,  
432and 0.26% SDS) and 500ng RNA probes. RNA:DNA hybrids were enriched  
433using 50ul T1 streptavidin beads (Invitrogen) through 30min incubation at  
434RT. Next, bead-bound hybrids were washed through a 15min incubation in  
435wash buffer1 (1X SSC and 0.1% SDS) with frequent vortexing, and then  
436washed three times with 500ul of pre-warmed (65 °C) wash buffer2 (0.1X  
437SSC and 0.1% SDS), then finally resuspended in nuclease-free water. The  
438resulting capture Hi-C libraries were amplified while bound to T1 beads,  
439and purified using AMPure XP beads, followed by sequencing.

440

#### 441**Promoter Capture Hi-C library sequencing, read alignment, and** 442**off-target read filtering**

443 Promoter Capture Hi-C library sequencing procedures were carried out as  
444 previously described according to Illumina HiSeq2500 or HiSeq4000  
445 protocols with minor modifications (Illumina, San Diego, CA). Read pairs  
446 from Promoter Capture Hi-C library were independently mapped to human  
447 genome hg19 using BWA-mem and manually paired with in house script.  
448 Unmapped, non-uniquely mapped, and PCR duplicate reads were  
449 removed. Trans-chromosomal read pairs and putative self-ligated  
450 products (<15kb read pairs) were also removed. Off-target reads were  
451 removed when both read pairs did not match the capture probe  
452 sequences. The resulting on-target rates in Promoter Capture Hi-C library  
453 ranged from 17% to 44% after removing PCR duplicate reads.

454

#### 455 **Promoter Capture Hi-C normalization**

456 Interaction frequencies obtained from Promoter Capture Hi-C were  
457 normalized in terms of DNA fragment resolution restricted by *HindIII*. We  
458 defined DNA fragments that spanned each *HindIII* restriction site. The  
459 start and the end of DNA fragments were defined by taking the midpoint  
460 of adjacent upstream and downstream restriction sites, respectively. We  
461 merged adjacent DNA fragments if the total length of the DNA fragments  
462 was less than 3kb. As a result, 510,045 DNA fragments were defined with  
463 a median length of 4.8kb. After that, we calculated raw interaction  
464 frequencies at DNA fragment resolution and performed normalization to  
465 remove experimental biases caused by intrinsic DNA sequence biases (GC  
466 contents, mappability, and effective fragment lengths), RNA probe

467synthesis efficiency bias, and RNA probe hybridization efficiency bias.  
468Highly variable RNA probe synthesis efficiency would greatly complicate  
469the control of experimental bias. However, if the efficiency bias was  
470reproducible, the bias can be computationally removed. To prove such  
471bias reproducibility, we performed RNA-seq with two sets of RNA probes  
472that were synthesized independently. The RNA-seq results can  
473quantitatively measure the amount of synthesized RNA probes, which is  
474an indicator of the probe synthesis efficiency. We observed highly  
475reproducible RNA-seq results (Pearson Correlation Coefficient = 0.98),  
476indicating reproducible probe synthesis efficiency. To address the high  
477complexity of different types of experimental biases, we defined a new  
478term named “Capturability”, which refers to the probability of the region  
479being captured. We assumed that “Capturability” represents all combined  
480experimental biases and can be estimated by the total number of capture  
481reads spanning a given DNA fragment divided by the total number of  
482captured reads in *cis*. We found that “Capturability” in each DNA fragment  
483is highly reproducible across samples with 0.95 Pearson correlation  
484coefficient between samples on average. Therefore, we defined universal  
485“Capturability” as the summation of all “Capturability” defined in each  
486sample and normalized raw interaction frequencies by considering  
487“Capturability” of two DNA fragments. During normalization, we processed  
488promoter-promoter interactions and promoter-other interactions  
489independently because promoter regions tend to show very high  
490“Capturability” as our capture probes were designed to target promoter

491regions. Also, we only considered promoter-centered long-range  
492interactions over 15kb and within 2Mb from TSS of each gene. We  
493denoted  $Y_{ij}$  to represent the raw interaction frequency between DNA  
494fragment  $i$  and  $j$  and  $C_i$  to represent “Capturability” defined in DNA  
495fragment  $i$ . We assumed  $Y_{ij}$  to follow a negative binomial distribution with  
496mean  $\mu$  and variance  $\mu + \alpha\mu^2$ . Here,  $\alpha > 0$  is a parameter to measure the  
497magnitude of over-dispersion. We then fitted a negative binomial  
498regression model as follows:  $\log u_{ij} = \beta_0 + \beta_1 BS(C_i) + \beta_2 BS(C_j)$ , where  $u_{ij}$  is  
499an raw interaction frequency between DNA fragment  $i$  and  $j$  with coverage  
500 $C_i$  and  $C_j$  and defined the residual  $R_{ij} = Y_{ij} / \exp(\dots)$  as a normalized  
501interaction frequency between DNA fragments  $i$  and  $j$ .  $BS$  represents a  
502basis vector obtained from  $B$ -spline regression, which applied to a vector  
503of values of input variable,  $C$ , during negative binomial regression model  
504fitting for robustness and memory efficient calculation.

505

## 506 **Identification of P-P and P-O pcHi-C long-range chromatin**

### 507 **interactions**

508 To identify significant pcHi-C chromatin interactions, we removed distance  
509 dependent background signals from normalized interaction frequencies.

510 Here, we assumed that normalized interaction frequency  $R_{ij}$  follows a

511 negative binomial distribution with mean  $\mu$  and variance  $\mu + \alpha\mu^2$ . Similar to

512 the interaction frequency normalization step above, we calculated the

513 expected interaction frequency at a given distance by fitting it to a

514 negative binomial regression model with basis vectors obtained from  $B$ -

515 spline regression of distance between two DNA fragments. We denoted  $E_d$   
516 to represent the expected interaction frequency at a given distance  $d$   
517 calculated from a negative binomial regression model. Distance  
518 dependent background signals were removed by taking signal to  
519 background ratio as follows:  $(R_{ij} + \text{avg}(R)) / (E_d + \text{avg}(R))$ , where  $d$   
520 indicates distance between DNA fragment  $i$  and  $j$ . We confirm that the  
521 average of normalized interaction frequencies against distance dependent  
522 background signals are close to one in all distance, indicating the  
523 successful elimination of distance dependent background signals using  
524 our method. Next, using 'fitDistr' function in propagate R package we  
525 found that 3-parameter Weibull distribution well follows the values of  
526 normalized interaction frequencies. Thus, we modeled background  
527 distribution of distance normalized interaction frequencies with 3-  
528 parameter Weibull distribution. Based on this, significant long-range  
529 chromatin interactions are defined when observed interaction frequencies  
530 show lower than 0.01 p-value thresholds by fitting distance background  
531 removed interaction frequencies with 3-parameter Weibull distribution. To  
532 eliminate false pHi-C interactions caused by experimental noise, we  
533 applied the criteria of minimum raw interaction frequencies (having more  
534 than 5 raw interaction frequencies), which is chosen by investigating  
535 reproducibility between biological replicates using lymphoblastoid and  
536 mesenchymal stem cell. Note that as the interaction frequencies in pHi-C  
537 are mostly zeros or close to zero, the distribution of p-values does not  
538 follow the uniform distribution, violating the basic assumption of FDR

539 calculation, which assumes that the null distribution follows uniform (0,1)  
540 distribution. Thus, we simulated normalized interaction frequencies that  
541 follow 3-parameter Weibull distribution in a sample specific manner, and  
542 computed the estimated FDR through multiple permutations. The  
543 estimated FDR through multiple permutation (n=1,000) for P-O and P-P  
544 pcHi-C interactions is 9% and 5% on average, respectively

545

### 546 ***in situ* Hi-C experiments and validation of pcHi-C long-range** 547 **chromatin interactions**

548 The visual inspection of normalized interaction frequencies between  
549 IMR90 Promoter Capture Hi-C and high resolution IMR90 Hi-C showed high  
550 consistency based on manual inspection despite pcHi-C having only 10%  
551 sequencing depth compared to high resolution Hi-C (Extended Data Fig.  
552 4a). Next, we compared the identified pcHi-C interactions with “loops”  
553 defined from IMR90, GM12878, dorsolateral prefrontal cortex, and  
554 hippocampus tissues using *in situ* Hi-C experiments (Extended Data Fig.  
555 4b-e). Although there is a huge discrepancy between the number of *in situ*  
556 Hi-C loops and pcHi-C interactions, we may consider ‘loops’ are a subset  
557 of high confident long-range chromatin interactions that involve ‘loop’  
558 domains but cannot cover all promoter-mediated long-range chromatin  
559 interactions. Loops of IMR90 and GM12878 *in situ* Hi-C result were  
560 obtained from previous publication<sup>13</sup>. Loops of dorsolateral prefrontal  
561 cortex and hippocampus were identified using HiCCUPS, distributed with  
562 Juicer v1.7.6<sup>13</sup>. The loops were called from Knight-Ruiz normalized 5kb,

56310kb, and 25kb resolution data, as these parameters were suggested for a  
564medium resolution Hi-C map by the authors of HiCCUPS. As a result, 7,722  
565and 8,040 loops were identified from dorsolateral prefrontal cortex and  
566hippocampus, respectively. We compared the identified pHi-C long-range  
567chromatin interactions to loops of *in situ* Hi-C data and measured the  
568reproducibility in terms of ROC curve (receiver operating characteristic  
569curve), a plot of the true positive rate against the false positive rate at  
570various threshold settings. Here, we set loops as true interactions. We  
571ranked all tested pHi-C DNA fragment pairs in terms of p-values and then  
572calculated the fraction of true positive and false positive to draw ROC  
573curve. We only considered “loops” emanating from promoter-containing  
574DNA fragments defined in our Promoter Capture Hi-C result. Each point on  
575the ROC curve indicates the true and false positive rate for each 1,000  
576false positive interactions. The area under the ROC curve is defined as an  
577ROC score and an ROC score of 1 indicates that the rank of DNA fragment  
578pairs matched by loops are always higher than all other tested DNA  
579fragment pairs according to pHi-C interaction p-values.

580

### 581 **Reproducibility of pHi-C chromatin interactions between** 582 **biological replicates**

583The reproducibility of pHi-C chromatin interactions between biological  
584replicates were measured in terms of ROC curve (Extended Data Fig. 4f).  
585Here, we set pHi-C interactions identified in one replicate as true  
586interactions. For the other replicate, we ranked all tested DNA fragment

587pairs in terms of p-values and then calculated the fraction of true positive  
588and false positive to draw ROC curve. The area under the ROC curve is  
589defined as an ROC score and an ROC score of 1 indicates that the rank of  
590all pcHi-C interactions identified in one replicate is always higher than all  
591other tested DNA fragment pairs in another replicate. Due to different  
592sequencing depths in each replicate, we first defined true interaction sets  
593with one replicate that identified fewer number of pcHi-C interactions than  
594the other replicate, then tested how these true interactions were well  
595detected in the other replicate. Both P-P and P-O interactions were  
596combined together for calculating ROC scores. Each dot in ROC curve  
597indicates the true positive rate at the corresponding false positive rate  
598with increment of 1% of false positive rate. We tested biological replicates  
599in the following 12 tissue/cell types: aorta (AO2/AO3, ROC score=0.79),  
600lung (LG1/LG2, ROC score=0.80), small bowel (SB1/SB2, ROC  
601score=0.83), spleen (SX1/SX3, ROC score=0.80), dorsolateral prefrontal  
602cortex (FC\_rep1/FC\_rep2, ROC score=0.92), left ventricle (LV1/LV3, ROC  
603score=0.85), mesenchymal stem cell (MSC\_rep1/MSC\_rep2, ROC  
604Score=0.99), hippocampus (HC\_rep1/HC\_rep2, ROC score=0.81), gastric  
605(GA2/GA3, ROC score=0.91), lymphoblastoid cell lines  
606(GM12878/GM19240, ROC score=0.98), right ventricle (RV1/RV3, ROC  
607Score=0.83), and pancreas (PA2/PA3, ROC score=0.73). Indeed, we  
608calculated Spearman's rank correlation of p values between replicates and  
609found that the average Spearman's rank correlation was around 0.40.

610

## 611 **Enrichment of pHi-C interactions regarding TAD, boundary, and** 612 **unorganized regions**

613 The TAD annotations for 22 samples by DomainCaller<sup>14</sup> with 2MB windows  
614 size were downloaded from the 3DIV database<sup>38</sup>. The regions between  
615 TADs were classified as “unorganized” when the gap is longer than 400kb,  
616 otherwise, the remaining regions were classified as “boundary”. Then, the  
617 types of pHi-C interactions were classified based on the location of DNA  
618 fragment’s centroid.

- 619 1. “Within TAD”, if both fragments’ centroids are located in the  
620 identical TAD.
- 621 2. “Within unorganized region”, if both fragments’ centroids are  
622 located in the identical unorganized region.
- 623 3. “Between different TADs”, if one fragment’s centroid is located in a  
624 TAD while another fragment’s centroid is located in a different TAD.
- 625 4. “Between TAD and boundary”, if one fragment’s centroid is located  
626 in a TAD while another fragment’s centroid is covered by boundary  
627 region.
- 628 5. “Between TAD and unorganized region”, if one fragment’s centroid  
629 is located in a TAD while another fragment’s centroid is located in  
630 an unorganized region.

631

## 632 **Annotation of ChromHMM 18-chromatin state to DNA fragments**

633 The pre-calculated chromatin state annotations were downloaded from  
634 the 18-state ChromHMM model established by Roadmap Epigenomics  
635 Project. As the genomic proportion of promoter and enhancer regions are  
636 relatively low, we assigned the chromatin states to DNA fragments based  
637 on the following priority order (TssA-EnhA1-EnhA2-TssFlnk-TssFlnkU-

638TssflnkD-EnhG1/G2-EnhWk-TssBiv-Enhbiv). For instance, the chromatin  
639state of a fragment was assigned as TssFlnkU, if the fragment contained  
640two annotations TssFlnkU and EnhWk. EnhG1 and EnhG2 annotations  
641were merged because of their low occurrence percentage. We considered  
642two promoter types (TssA and TssBiv) according to ChromHMM  
643annotations and investigated the preference of their interacting partners.  
644For each promoter type, the occurrence of each chromatin status at  
645interacting DNA fragments was divided by the total number of interacting  
646DNA fragments. This fraction value of each chromatin status was  
647normalized against the genomic fraction of each chromatin status. KS-test  
648was performed to measure the statistical significance of each chromatin  
649status at interacting DNA fragments between TssA and TssBiv promoters.  
650

### 651**Analysis with a 50-chromatin-state ChromHMM model**

652To supplement our analysis with the ChromHMM 18-chromatin state  
653model, we conducted in-depth investigations with 5 samples, including H1  
654embryonic stem cell, mesendoderm, mesenchymal stem cell, trophoblast,  
655and IMR90, using a 50-state ChromHMM model produced by the Roadmap  
656Epigenomics Project<sup>35</sup>. The ChromHMM model utilized combination of 29  
657chromatin marks to generate a 50-state ChromHMM model. To be  
658consistent with the 18-state ChromHMM model, we used the same  
659definition for TssA and TssBiv promoter containing fragments, but  
660chromatin state of their interacting partners was further refined using the

66150-state ChromHMM model. The statistical test was performed as  
662described in the analysis with the 18-chromatin-state ChromHMM model.

663

#### 664**Identification of extensively interacting DNA fragments**

665In order to identify DNA fragments that showed extensive long-range  
666interactions with multiple promoters, we systematically defined these  
667promiscuously interacting DNA fragments from P-P pHi-C interaction  
668maps and P-O pHi-C interaction maps, respectively. For each cell or  
669tissue-type, we selected frequently interacting DNA fragments with  
670multiple promoters in terms of 0.01 Poisson p value cutoff.

671

#### 672**Identification of TF clusters in H1-hESC and GM12878**

673Transcription factor ChIP-seq datasets on human lymphoblastoid cell lines  
674(GM12878) and human embryonic stem cell (H1-hESC) were collected  
675from ENCODE. These ChIP-seq reads were aligned against human genome  
676hg19 using BWA-mem with default parameters. Non-uniquely mapped,  
677low quality (MAPQ<10), and PCR duplicate reads were removed. Peak  
678calling of individual ChIP-seq experiments was performed with MACS2  
679callpeak with default parameters<sup>39</sup>. We defined TF clusters by calling  
680peaks from combined bed files of TF peaked regions using MACS2  
681bdgpeakcall. The regions occupied by multiple TF peaks were recognized  
682as TF clusters. To remove parameter dependent bias, we retrieved TF  
683clusters 40 times with various parameter sets as following; minimum # of  
684TFs within cluster (5 or 10), minimum length of cluster from 100bp to

6851600bp, and maximum gap length within cluster from 100bp to 51.2kb.

686Final TF clusters were defined when the region was detected as TF

687clusters more than 50 times from 100 different parameter sets.

688

### 689**Enrichment analysis of TF clusters and super-enhancers**

690In order to calculate the enrichment of TF clusters or super-enhancers at

691extensively interacting DNA fragments (EIF), we counted the number of

692matched TF clusters and super-enhancers. The list of super-enhancers

693was obtained from the 3DIV database<sup>38</sup>. Permutation test was performed

694to calculate the expected values. Using Bedtools shuffleBed, we

695generated random genomic locations that resemble actual TF clusters

696with the same size but different genomic coordinates. Bedtools

697intersectBed identified any overlap between EIF and TF clusters or random

698genomic locations. Standard deviations of error bars in the random

699genomic locations were calculated from 10,000 random data sets. In order

700to test the enrichment of TF clusters compared to typical TF peaks, we

701generated random genomic locations that resemble actual TF clusters

702with the same size but different genomic coordinates matched to typical

703TF peaks. Standard deviations of error bars in the typical TF peaks were

704calculated from 10,000 random data sets. Similarly, enrichment analysis

705of super-enhancers was conducted by generating random genomic

706locations of the same size as super-enhancers but at different genomic

707coordinates. We also conducted the enrichment test with typical

708enhancers. We revealed that P-O EIFs highly co-exist with super-enhancer

709regions, rather than typical enhancers and genomic background for most  
710of the samples, except two samples, lymphoblastoid cell lines and gastric  
711tissue. Note that half of lymphoblastoid P-O EIFs are co-occupied with  
712typical enhancers that are classified as super-enhancers in other  
713cell/tissue types.

714

### 715**Comparison between eQTL associations and P-O interactions**

716In order to test the enrichment for P-O pHi-C chromatin interactions in  
717significant eQTL associations, we compared P-O pHi-C interactions to  
718significant eQTL associations in the matching tissue types. The eQTL  
719associations were downloaded directly from GTEx Portal (downloaded on  
720Nov. 10<sup>th</sup>, 2017) for all matching tissue types (n=14, adrenal gland, aorta,  
721dorsolateral prefrontal cortex, brain hippocampus, sigmoid colon,  
722esophagus, left heart ventricle, liver, lung, ovary, pancreas, small  
723intestine terminal ileum for small bowel, spleen, and stomach for gastric).  
724First, the significant eQTLs defined by GTEx (q-value  $\leq 0.05$ ) were filtered  
725so that only the eQTL variants within the fragments that involve P-O pHi-  
726C interactions remain for comparison. Then, we removed pHi-C  
727interactions beyond 1Mb in distance to match the range of eQTL  
728association, and discarded eQTL associations with distance below 15kb to  
729match the valid interaction cutoff. The filtered, significant eQTL  
730associations were compared with pHi-C and randomized interactions in  
731the same condition. Here, we only considered P-O pHi-C interactions with  
732DNA fragments that do not harbor multiple promoters. For the random

733 expectation, we generated a simulated pHi-C interaction pool by creating  
734 all possible combinations of DNA fragments with no TSS and the protein  
735 coding genes that exist within the distance range. The pHi-C interactions  
736 that exist in any of the tissue/cell type were removed from the control  
737 interaction pool for the enrichment analysis. To avoid variation caused by  
738 the difference in distance between pHi-C interactions and eQTL  
739 associations, we created distance matched control, in which the number  
740 of pHi-C interactions was stored at the interval of 40kb, and the same  
741 number of interactions was drawn randomly from the control interaction  
742 pool. The number of randomized interactions drawn from each  
743 chromosome was matched to the pHi-C interactions. The standard  
744 deviation was obtained by permuting the random expectation with 1,000  
745 iterations and was used to calculate the statistical confidence  
746

747 To illustrate the filtering process of the eQTL data, for example, the  
748 549,763 significant eQTLs in adrenal gland were reduced to 237,181 after  
749 collecting eQTLs located in the DNA fragments without TSS and discarding  
750 eQTL association with the distance below 15kb and with a pseudogene  
751 target. This filtered set of significant eQTL associations was used for  
752 enrichment test for both pHi-C and randomized interactions. The number  
753 of total tested significant eQTL association, 19,996 in case of adrenal  
754 gland, in Supplementary Table 11, indicates the number of significant  
755 eQTLs located in the DNA fragments that are associated with the pHi-C  
756 interactions in the corresponding cell/tissue type.

757

**758 Variations in H3K27ac signals at promoters and cREs connected  
759 by P-O interactions**

760 We conducted correlation analysis of H3K27ac signals across all available  
761 cell/tissue types for each promoter-cRE pair connected by P-O interactions  
762 in at least one cell/tissue type analyzed. First, we defined putative distal  
763 *cis*-regulatory elements (cREs) marked by H3K27ac peaks across all 27  
764 cell/tissue types. We merged these elements if the peaks are within 3kb of  
765 each other, then we defined cRE-containing DNA fragment when the DNA  
766 fragment harbors at least one *cis*-regulatory element. When a DNA  
767 fragment contained both TSS and cRE, we defined the fragment as a  
768 promoter-containing DNA fragment instead of a cRE-containing DNA  
769 fragment because our experiment is designed to target promoter regions.  
770 We used input normalized H3K27ac RPKM values by taking log<sub>2</sub>  
771 transformation as H3K27ac signals at promoters and cREs. Pearson  
772 correlation coefficient values were calculated for each promoter-cRE pair  
773 connected by pHi-C interactions after excluding cREs spanning adjacent  
774 DNA fragments and visualized as a box plot. Random expectation values  
775 were calculated after randomization of H3k27ac signals at promoters and  
776 cREs. Distance matching random expectation values were calculated after  
777 random selection of cRE-promoter pairs by controlling distance  
778 information as same as identified cRE-promoter pairs.

779

**780 Analysis of H3K27ac signals at cREs and expression of target**  
**781 genes connected by cell/tissue specific cRE-promoter pairs**

782 In order to investigate cell/tissue-specific cRE-promoter pairs, for each  
783 cell/tissue-type unique cRE-promoter pairs were collected and then  
784 distance normalized pHi-C interaction frequencies of corresponding P-O  
785 pHi-C interactions were obtained across all cell/tissue types. We only  
786 considered a unique P-O interaction pair when multiple cREs are located in  
787 a same DNA fragment and target a same promoter. The cell/tissue-  
788 specific cRE-promoter pairs exhibit strong enrichment of pHi-C  
789 interaction frequencies in the corresponding cell/tissue type but depleted  
790 in other cell/tissue types, validating the cell/tissue-specificity of these cRE-  
791 promoter pairs. Statistical significance of pHi-C interaction frequencies  
792 was tested by conducting KS-test between mean of pHi-C interaction  
793 frequencies in the matched cell/tissue types (values in diagonal in Fig. 2f)  
794 and those in other cell/tissue types (values in off diagonal in Fig. 2f).

795

796 In order to investigate cell/tissue-specific activity of cREs connected by  
797 cell/tissue-specific cRE-promoter pairs, we identified group of cREs that  
798 are connected by unique cRE-promoter pairs for each cell/tissue type.  
799 After that, H3K27ac signals were calculated for each cRE across all  
800 cell/tissue types and these values were normalized by taking z-score  
801 transformation to obtain relative H3K27ac enrichment signals. The mean  
802 values of normalized H3K27ac signals were calculated for each group of  
803 cREs in each cell/tissue type. KS-test was performed between the mean

804 values in the corresponding cell/tissue types (values in diagonal in Fig. 2g)  
805 and those in other cell/tissue types (values in off diagonal in Fig. 2g).

806

807 In order to investigate expression levels of target genes connected by  
808 cell/tissue-specific cRE-promoter pairs, we first defined a group of genes  
809 that are connected by unique cRE-promoter pairs more than twice for  
810 each cell/tissue-type. After that, gene expression levels (FPKM) were  
811 calculated for each gene across all cell/tissue types. Relative gene  
812 expression levels were obtained by taking z-score transformation for each  
813 gene across all cell/tissue types. The mean values of z-score transformed  
814 FPKM values were calculated for each group of genes in each cell/tissue  
815 type. KS-test was performed between the mean values in the  
816 corresponding cell/tissue types (values in diagonal in Fig. 2h) and those in  
817 other cell/tissue types (values in off diagonal in Fig. 2h).

818

### 819 **Comparison between eQTL associations and P-P chromatin** 820 **interactions**

821 In order to assess the enrichment for promoter-promoter pHi-C  
822 interactions in the significant eQTL associations, we computed the number  
823 of P-P pHi-C interactions matched to the significant eQTL associations  
824 (downloaded on Nov. 10<sup>th</sup>, 2017). For the tested tissue types (n=13,  
825 adrenal gland, aorta, dorsolateral prefrontal cortex BA9, hippocampus,  
826 sigmoid colon, left ventricle, liver, lung, ovary, pancreas, small intestine  
827 terminal ileum for small bowel, spleen, and stomach for gastric), we

828 considered only the eQTLs that are located within 2.5kb from a TSS of a  
829 protein coding gene. For accurate comparison, we removed P-P chromatin  
830 interactions beyond 1Mb in distance to match the range of eQTL  
831 association, and discarded eQTL associations with distance below 15kb to  
832 match the valid interaction cutoff. Finally, the significant eQTLs were  
833 filtered by collecting only the eQTLs within the fragments that involve P-P  
834 pcHi-C interactions in the corresponding cell/tissue and by removing  
835 eQTLs that target pseudogenes. Then, the number of filtered significant  
836 eQTLs that match P-P pcHi-C interactions was counted. The DNA  
837 fragments that harbor multiple promoters were removed from the  
838 analysis. For the random expectation, we created a control pool of all P-P  
839 pairs within the range of 15kb to 1Mb, selected the same number of  
840 random P-P pairs as used in significant eQTL comparison, and counted the  
841 matched number of random P-P pairs with P-P pcHi-C interactions. The P-P  
842 pcHi-C interactions that exist in any of the tissue/cell type were removed  
843 from the control interaction pool for the enrichment analysis. In addition,  
844 to avoid variation caused by the difference in distance between pcHi-C  
845 interactions and eQTL associations, we created distance matched control,  
846 in which the number of pcHi-C interactions was stored at the interval of  
847 40kb, and the same number of interactions was drawn randomly from the  
848 randomized interaction pool. In addition, the number of randomized  
849 interactions drawn from each chromosome was matched to the pcHi-C  
850 interactions. The standard deviation was obtained by permuting the

851 random expectation with 1,000 iterations and was used to calculate the  
852 statistical significance.

853

#### 854 **Visualization of eQTL-supported P-P and P-O chromatin**

#### 855 **interactions**

856 The pcHi-C interactions that matched significant eQTLs were visualized by  
857 LocusZoom<sup>40</sup>. We collected and merged significant and all tested eQTLs  
858 for each tissue type and extracted the relevant p-values and SNP IDs for a  
859 queried gene. Then, LocusZoom was run with default parameters to show  
860 the pcHi-C interaction and its eQTL associations surrounding the region.

861

#### 862 **Experimental validation of enhancer-like function of promoters**

863 H1-hESC was cultured in mTeSR1 medium on Matrigel coated plates<sup>33</sup>. To  
864 knockout the core promoter regions of *ZNF891* (chr12:133706994) and  
865 *ARIH2OS* (chr3:48956862) in H1-hESC, we utilized CRISPR/Cas9 RNP  
866 method as previously described by Diao, et al.<sup>33</sup>. Briefly, we used *in vitro*  
867 synthesized CRISPR crRNA and CRISPR tracrRNA (IDT) with the sequences  
868 specified below.

869 *ZNF891* sgRNAs 5p-1: GCGTCCGTGACGCACAGACC

870 *ZNF891* sgRNAs 5p-2: GACCAGGCCCTCTGCGGGG

871 *ZNF891* sgRNAs 3p-1: AGGCTGGGGCGCGTGCGTAA

872 *ZNF891* sgRNAs 3p-2: GTGCGTAACGGTGTGTGTTG

873 *ZNF891* genotyping primer 5p: GTCCTCAGTGCCTGCCTC

874 *ZNF891* genotyping primer 3p: CAGCAACAGCAAACAGAGAAC

875 *ARIH2OS* sgRNAs 5p-1: GCTCCCAAAGATGACTCGAG

876 *ARIH2OS* sgRNAs 5p-2: GACTCGAGTGGTGAGCCCCG

877 *ARIH2OS* sgRNAs 3p-1: GGAGAAGTCATCCAAGAACG

7538

76

878ARIH2OS sgRNAs 3p-2: CGCTATGACAGAAAGTTCTA

879ARIH2OS genotyping primer 5p: CATCTAGGCCCTCTCTCCCT

880ARIH2OS genotyping primer 3p: TCAGCAATTTTCGTTTCAAATC

881

882Each of the core promoter was knocked-out by two sets of sgRNA pairs to

883avoid the potential off-target effect caused by CRISPR/Cas9 genome

884editing. The Cas9 recombinant protein was purchased from NEB (Cat

885M0386M) and the Cas9/crRNA/tracrRNA was assembled *in vitro* by

886following the previously described protocol<sup>33</sup>. The RNP complex was

887electro-transfected into POU5F1-eGFP hESC reporter line with Neon

888Transfection System 10 $\mu$ l kit (ThermoFisher Scientific, Cat#: MPK1096)

889with the default electrotransfection protocol. Seven days after post-

890transfection, individual colonies were picked and expanded, followed by

891genotyping and in-depth analysis. After genotype validation, we

892performed RNA-seq using Ovation<sup>®</sup> RNA-Seq System V2 (NuGEN) as

893previously described<sup>41</sup>.

894

895**RNA-seq data analysis between WT and mutants upon promoter**

896**deletion**

897Raw RNA-seq fastq files were aligned to the reference genome (hg19)

898using BWA-mem. Duplicate reads were discarded with Picard to avoid any

899artifact caused by the amplification step originated from Ovation<sup>®</sup> RNA-

900Seq System V2 (NuGEN). Then, FPKM values were calculated using

901Cufflinks with GENCODE v19 annotation. Reproducibility between

902biological replicates were measured (PCC of FPKM for WT = 0.98, *ZNF891*

903 promoter deletion clone #1 = 0.99, *ZNF891* promoter deletion clone #2 =  
904 0.99, *ZNF891* promoter deletion clone #3 = 0.99, and *ARIH2OS* promoter  
905 deletion clone #1 = 0.98). FPKM values of *ZNF84* and *NCKIPSD* were  
906 investigated as distal target genes of *ZNF891* and *ARIH2OS*, respectively,  
907 between mutant and WT to test the effect of deletion of core promoters  
908 on distal target genes.

909

### 910 **Experimental validation of promoter-proximal eQTL distal target** 911 **genes**

912 In order to validate the distal target genes of promoter-proximal eQTLs  
913 identified by pHi-C results, we designed sgRNA sequences targeting +/-  
914 5bp of the eQTLs in H1-hESC and cloned the sgRNAs into lentiCRISPRv2  
915 backbone, followed by lentiviral preparation, infection and Puromycin  
916 selection as previously described<sup>33</sup>. Two weeks after the infection, single  
917 clones were selected and genotyped to confirm the mutations on the  
918 targeted eQTL sites (genotyping PCR results are listed in the oligo file).  
919 Total RNA was purified from each single clone and subjected to RT-qPCR  
920 analysis as previously described (Genotyping PCR primers are listed in the  
921 oligo file)<sup>33</sup>. To conduct statistical analysis, two separate sgRNAs were  
922 generated, which target the same eQTL. Then, three clones were isolated  
923 and cultured for a single sgRNA in order to induce the knockout, and each  
924 of these clones was considered as a biological replicate. Each clone was  
925 consisted of technical triplicates for the stable measurement of the  
926 expression during RT-qPCR experiment.

927

928chr9:139305041\_1 sgRNA in H1-hESC: GCCTTGGGCCGTCGGCGAGGGGG  
929chr9:139305041\_2 sgRNA in H1-hESC: TGGGCCGTCGGCGAGGGGGAGGG  
930chr17:18128865\_1 sgRNA in H1-hESC: GCGGGGCCGGCCTGCACGGGGG  
931chr17:18128865\_2 sgRNA in H1-hESC: CGCGCGGGGCCGGCCTGCACGG  
932chr14:104029246\_1 sgRNA in H1-hESC: CGAAGCCCGAGGAAGCGCGGGCGG  
933chr14:104029246\_2 sgRNA in H1-hESC: CGGCAGGGTCGCGAAGCCCGAGG  
934chr3:184032262\_1 sgRNA in H1-hESC: GGCAAATCCCATGTGCTCGGCGG  
935chr3:184032262\_2 sgRNA in H1-hESC: GGGGGCAAATCCCATGTGCTCGG

936

937chr9:139305041\_F genotyping primer: CGCTGGTAGCCCGACATC  
938chr9:139305041\_R genotyping primer: CCCCCTTCAGTCGTAC  
939chr17:18128865\_F genotyping primer: CCCAGTTCACCATTGTCTGG  
940chr17:18128865\_R genotyping primer: AACCGAACTTCATCATCTTGC  
941chr14:104029246\_F genotyping primer: GAGGCAGCCTGGAGTGAC  
942chr14:104029246\_R genotyping primer: GAGAAAGGTCTTCTTCCCG  
943chr3:184032262\_F genotyping primer: AATGAACTAAAGAATCGCGGAA  
944chr3:184032262\_R genotyping primer: CACAGACGTAGTCCACAACCAT

945

#### 946**Experimental validation of distal target genes for disease-**

#### 947**associated genetic variants**

948In order to validate the distal target genes of disease-associated genetic  
949variants (GWAS-SNPs) identified by pHi-C results, we designed sgRNA  
950sequences targeting +/- 5bp of the GWAS-SNPs in lymphoblastoid cells,  
951and cloned the sgRNAs into lentiCRISPRv2 backbone as described above.  
952Two weeks after the infection, single clones were selected and genotyped  
953to confirm the mutations on the targeted GWAS-SNP sites (genotyping  
954PCR results are listed in the oligo file). Total RNA was purified from each  
955single clone and subjected to RT-qPCR analysis as previously described  
956(Genotyping PCR primers are listed in the oligo file)<sup>33</sup>. To conduct

8141

82

957 statistical analysis, two separate sgRNAs were generated, which target  
958 the same GWAS SNP. Then, two clones were isolated and cultured for a  
959 single sgRNA in order to induce the knockout, and each of these clones  
960 was considered as a biological replicate. Each clone was consisted of  
961 technical triplicates for the stable measurement of the expression during  
962 RT-qPCR experiment.

963

964 chr5.96297527 sgRNA in GM12878: TGCCATTCAGTCTATAGATCTGG  
965 chr17.38032460 sgRNA in GM12878: TGGGCTTTGGCTGGGCGCAGTGG  
966 chr17.38023745 sgRNA in GM12878: GGGCTCCATCCCTACAGAAAAGG  
967 chr3.52707026 sgRNA in GM12878: GAGTTTTGCTCTTATTGTCCAGG  
968 chr3.52703615 sgRNA in GM12878: AGTTATTACAAATAACATCATGG  
969 chr3.52728804 sgRNA in GM12878: TCCTGGAAGATAGCATGCGTGGG  
970 chr3.52706724 sgRNA in GM12878: GGTCTCGAACTCCTGCACTCAGG

971

972 chr5: 96297527\_F genotyping primer: ACCAGTTTACACGAATCATCCC  
973 chr17:38032460\_F genotyping primer: TAGAGACAGAGTTTCGCCCTGT  
974 chr17:38023745\_F genotyping primer: TGGGCTCTCTCTACTAACCAGC  
975 chr3:52707026\_F genotyping primer: TGACAGCAAGAGAGGAAAGATG  
976 chr3:52703615\_F genotyping primer: TCAAATGAAGTTCCAGGAGACA  
977 chr3:52728804\_F genotyping primer: ACTTGTAAGGCAGATGGAGAC  
978 chr3:52706724\_F genotyping primer: GTTCAAGTGATTCTCCTGCCTC  
979 chr5: 96297527\_R genotyping primer: ACTTCATCATGGGCAGTAAACC  
980 chr17:38032460\_R genotyping primer: AGGACCATTCTGTTTTCTTCA  
981 chr17:38023745\_R genotyping primer: GTGACCTTGCTTTAAAATGGG  
982 chr3:52707026\_R genotyping primer: AGGTGGGAGAATTGCTTGAAC  
983 chr3:52703615\_R genotyping primer: AACCTGTCAGCTAAGGTTCCAA  
984 chr3:52728804\_R genotyping primer: GCAAATTCAACCTAATCCGAAG  
985 chr3:52706724\_R genotyping primer: ATGCCTGTAATCCCAACACTTT

986

### 987 **Extended GWAS-SNPs with high LD structure**

988GWAS-SNPs were obtained from GWAS catalogue database (version1.0.1,  
989downloaded on February 2018) and selected with p-value cutoff of  $10^{-5}$   
990with minor manual curations. As GWAS-SNPs obtained from GWAS catalog  
991database contain tag SNP information only, we extended the GWAS-SNP  
992information using linkage disequilibrium (LD) structure. LD scores were  
993calculated using PLINK for five different populations obtained from 1000  
994genome phase 3 data. For each tag SNP, we included all associated SNPs  
995that had tight LD scores ( $>0.8$ ) across all five populations (AFR, AMR, EAS,  
996EUR, and SAS). With the p-value cutoff of  $10^{-5}$ , we collected 42,674  
997significant GWAS-SNPs across 2,310 GWAS mapped traits and expanded  
998this list to 180,893 by including LD information. Then, putative target  
999genes of GWAS-SNPs were identified by aggregating all unique pHi-C  
1000interactions. We noted that the cutoff value of high LD association is  
1001arbitrarily determined by considering a stringent cutoff value presented in  
1002a set of previous studies to minimize additional noise in the data analysis.

1003

#### 1004**Enrichment test of disease genes in putative GWAS-SNP target** 1005**genes**

1006The list of putative disease associated genes was downloaded from  
1007GeneCard database, obtaining 9,989 disease-associated genes. Then, we  
1008defined putative target genes of GWAS-SNPs associated with Parkinson  
1009disease by using pHi-C interactions or the nearest gene information,  
1010respectively. Then, we counted the number of matched disease-  
1011associated genes in each set of putative GWAS-SNP target genes.

1012

1013**Clustering of GWAS mapped traits based on putative target gene**  
1014**similarities**

1015The “mapped traits” were obtained from GWAS catalog database  
1016(version1.0.1, downloaded on February 2018), and paired with their  
1017corresponding GWAS SNPs. Then, putative target genes for each GWAS  
1018SNP were obtained by the unique and aggregated pHi-C interactions.  
1019After defining putative target genes and their target frequency for each  
1020trait, we constructed a 1442 by 1442 correlation matrix where each entry  
1021indicates a similarity score between the mapped traits in terms of the  
1022Pearson correlation coefficient (PCC), for which only the traits with a total  
1023gene count greater than 5 were considered. The correlation matrix was  
1024subjected to K-means clustering (n=30) using Euclidean distance, and the  
1025cluster containing ungrouped terms was excluded in further analysis to  
1026eliminate miscellaneous terms. To avoid having a predetermined number  
1027of clusters, the remaining 687 traits were rearranged in a correlation  
1028matrix in terms of their hierarchical relationship (Pearson uncentered and  
1029complete linkage). The final hierarchically clustered correlation matrix  
1030showed a clear organization of 40 clusters with a threshold of dendrogram  
1031height, 0.9. Fig. 4c was drawn by using the nearest gene of GWAS SNPs.  
1032After defining the list of nearest genes for each mapped trait, we again  
1033measured the similarity between the mapped traits by calculating the  
1034Pearson correlation coefficient. We presented similarity values between  
1035the mapped traits as in the same order of mapped traits in Fig. 4b.

1036 Similarly, Fig. 4d was drawn by using the GWAS SNPs alone. We measured  
1037 the similarity of the mapped traits by calculating the Pearson correlation  
1038 coefficient between GWAS SNPs of each trait, and presented the values as  
1039 in the same order of mapped traits in Fig. 4b.

1040

#### 1041 **Analysis of functional enrichment using DAVID**

1042 To identify the enriched biological pathways in the GWAS mapped traits  
1043 for the clusters, we extracted putative target genes associated with each  
1044 cluster. Then, we performed Gene Ontology (GO) analysis using DAVID  
1045 (6.8 version) to obtain the list of enriched biological pathways for each  
1046 cluster with a cutoff p-value of  $10^{-3}$  by using the GO\_BP annotation  
1047 selection. After that we constructed 40 (number of clusters) by 126  
1048 (number of GO\_BP annotations) matrix where each entry indicates  
1049  $-\log_{10}(\text{p-value})$  of corresponding GO\_BP annotation. Next, we performed  
1050 hierarchical clustering in respect to the enriched biological pathways by  
1051 Pearson correlation matrix and average linkage parameter. In  
1052 Supplementary Table 17, we presented GO\_BP annotation information.

1053

1054 To see the effect of multiple TSS co-existing in a DNA fragment during  
1055 gene set enrichment analysis, we calculated the number of genes that are  
1056 located in the defined DNA fragments for all genes and the genes in  
1057 cluster 38. To see the effect of fragment-sharing TSS of genes on the  
1058 enriched biological pathways, we submitted the genes in cluster 38 for  
1059 enriched pathway analysis using three different queries; 1) total genes in

1060the cluster, 2) random selection of genes in case of fragment-sharing, and  
10613) after removal of the fragment-sharing genes, as illustrated in  
1062Supplementary Table 18. We did not observe any significant effect on  
1063gene set enrichment analysis caused by promoters shared by the same  
1064*Hind*III fragment with at least one other promoter.

1065

1066

1067

1068

1069

## 1070References

10711. Welter, D. *et al.* The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res* **42**, D1001-6 (2014).  
1072
10732. Maurano, M.T. *et al.* Systematic localization of common disease-associated variation in regulatory DNA. *Science* **337**, 1190-5 (2012).  
1074
10753. Hindorf, L.A. *et al.* Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci U S A* **106**, 9362-7 (2009).  
1076  
1077
10784. Lettice, L.A. *et al.* A long-range Shh enhancer regulates expression in the developing limb and fin and is associated with preaxial polydactyly. *Hum Mol Genet* **12**, 1725-35 (2003).  
1079  
1080
10815. Uslu, V.V. *et al.* Long-range enhancers regulating Myc expression are required for normal facial morphogenesis. *Nat Genet* **46**, 753-8 (2014).  
1082
10836. Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in Humans. *N Engl J Med* **373**, 895-907 (2015).  
1084
10857. Smemo, S. *et al.* Obesity-associated variants within FTO form long-range functional connections with IRX3. *Nature* **507**, 371-5 (2014).  
1086
10878. Yu, M. & Ren, B. The Three-Dimensional Organization of Mammalian Genomes. *Annu Rev Cell Dev Biol* **33**, 265-289 (2017).  
1088
10899. de Wit, E. *et al.* The pluripotent genome in three dimensions is shaped around pluripotency factors. *Nature* **501**, 227-31 (2013).  
1090
109110. Sanyal, A., Lajoie, B.R., Jain, G. & Dekker, J. The long-range interaction landscape of gene promoters. *Nature* **489**, 109-13 (2012).  
1092
109311. Dixon, J.R. *et al.* Chromatin architecture reorganization during stem cell differentiation. *Nature* **518**, 331-6 (2015).  
1094
109512. Jin, F. *et al.* A high-resolution map of the three-dimensional chromatin interactome in human cells. *Nature* **503**, 290-4 (2013).  
1096
109713. Rao, S.S. *et al.* A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. *Cell* **159**, 1665-80 (2014).  
1098
109914. Dixon, J.R. *et al.* Topological domains in mammalian genomes identified by analysis of chromatin interactions. *Nature* **485**, 376-80 (2012).  
1100
110115. Tang, Z. *et al.* CTCF-Mediated Human 3D Genome Architecture Reveals Chromatin Topology for Transcription. *Cell* **163**, 1611-27 (2015).  
1102
110316. Sahlen, P. *et al.* Genome-wide mapping of promoter-anchored interactions with close to single-enhancer resolution. *Genome Biol* **16**, 156 (2015).  
1104
110517. Jager, R. *et al.* Capture Hi-C identifies the chromatin interactome of colorectal cancer risk loci. *Nat Commun* **6**, 6178 (2015).  
1106
110718. Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C. *Nat Genet* **47**, 598-606 (2015).  
1108
110919. Dryden, N.H. *et al.* Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. *Genome Res* **24**, 1854-68 (2014).  
1110
111120. Martin, P. *et al.* Capture Hi-C reveals novel candidate genes and complex long-range interactions with related autoimmune risk loci. *Nat Commun* **6**, 10069 (2015).  
1112  
1113
111421. Javierre, B.M. *et al.* Lineage-Specific Genome Architecture Links Enhancers and Non-coding Disease Variants to Target Gene Promoters. *Cell* **167**, 1369-1384 e19 (2016).  
1115  
1116
111722. Freire-Pritchett, P. *et al.* Global reorganisation of cis-regulatory units upon lineage commitment of human embryonic stem cells. *Elife* **6**(2017).  
1118
111923. Siersbaek, R. *et al.* Dynamic Rewiring of Promoter-Anchored Chromatin Loops during Adipocyte Differentiation. *Mol Cell* **66**, 420-435 e5 (2017).  
1120
112124. Rubin, A.J. *et al.* Lineage-specific dynamic and pre-established enhancer-promoter contacts cooperate in terminal differentiation. *Nat Genet* **49**, 1522-1528 (2017).  
1122
112325. Orlando, G. *et al.* Promoter capture Hi-C-based identification of recurrent noncoding mutations in colorectal cancer. *Nat Genet* (2018).  
1124

112526. Leung, D. *et al.* Integrative analysis of haplotype-resolved epigenomes across human tissues. *Nature* **518**, 350-354 (2015).
112727. Schmitt, A.D. *et al.* A Compendium of Chromatin Contact Maps Reveals Spatially Active Regions in the Human Genome. *Cell Rep* **17**, 2042-2059 (2016).
112928. Thurman, R.E. *et al.* The accessible chromatin landscape of the human genome. *Nature* **489**, 75-82 (2012).
113129. Whyte, W.A. *et al.* Master transcription factors and mediator establish super-enhancers at key cell identity genes. *Cell* **153**, 307-19 (2013).
113330. Consortium, G.T. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648-60 (2015).
113531. Zhang, Y. *et al.* Chromatin connectivity maps reveal dynamic promoter-enhancer long-range associations. *Nature* **504**, 306-10 (2013).
113732. Rajagopal, N. *et al.* High-throughput mapping of regulatory DNA. *Nat Biotechnol* **34**, 167-74 (2016).
113933. Diao, Y. *et al.* A tiling-deletion-based genetic screen for cis-regulatory element identification in mammalian cells. *Nat Methods* **14**, 629-635 (2017).
114134. Engreitz, J.M. *et al.* Local regulation of gene expression by lncRNA promoters, transcription and splicing. *Nature* **539**, 452-455 (2016).
114335. Roadmap Epigenomics, C. *et al.* Integrative analysis of 111 reference human epigenomes. *Nature* **518**, 317-30 (2015).
114536. Richard, M., Drouin, R. & Beaulieu, A.D. ABC50, a novel human ATP-binding cassette protein found in tumor necrosis factor- $\alpha$ -stimulated synoviocytes. *Genomics* **53**, 137-45 (1998).
114837. Lieberman-Aiden, E. *et al.* Comprehensive mapping of long-range interactions reveals folding principles of the human genome. *Science* **326**, 289-93 (2009).
115038. Yang, D. *et al.* 3DIV: A 3D-genome Interaction Viewer and database. *Nucleic Acids Res* **46**, D52-D57 (2018).
115239. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol* **9**, R137 (2008).
115440. Pruim, R.J. *et al.* LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* **26**, 2336-7 (2010).
115641. Dahl, J.A. *et al.* Broad histone H3K4me3 domains in mouse oocytes modulate maternal-to-zygotic transition. *Nature* **537**, 548-552 (2016).

1158

1159

1160 **Supplementary Information** is linked to the online version of the paper

1161 at [www.nature.com/ng](http://www.nature.com/ng).

1162

### 1163 **Acknowledgement**

1164 We thank members of the Ren laboratory for support and critical

1165 suggestions throughout the course of this work. We are thankful to Dr.

1166 Naoki Nariai (UCSD) for sharing LD information. This work was funded by

1167 in part by the Ludwig Institute for Cancer Research (to B.R.), NIH

1168(U54HG006997 and 1R01ES024984, to B.R.), the Ministry of Science, ICT,  
1169and Future Planning through the National Research Foundation in Republic  
1170of Korea (2017R1C1B2008838 to I. J.), Korean Ministry of Health and  
1171Welfare (HI17C0328 to I. J.), and SUHF Fellowship (to I.J.).

1172

### 1173**Author Contributions**

1174Ij, AS, YD and BR conceived the study. Ij, AS, and YD performed  
1175experiments with assistance from TL, CT, and SC. Ij, AJL, and DY  
1176performed data analysis with assistance from JE, MC, ZC, and CLB. DK  
1177supervised data analysis by DY. CK, EM, and CLB contributed to provide  
1178human brain tissue samples. BL and SK contributed to sequencing and  
1179initial data processing. Ij prepared the manuscript with assistance from  
1180AS, YD, AJL, JE, and BR. All authors read and commented on the  
1181manuscript.

1182

### 1183**Author Information**

1184Reprints and permissions information is available at  
1185[www.nature.com/reprints](http://www.nature.com/reprints). The authors declare no competing financial  
1186interests: details are available in the online version of the paper. Readers  
1187are welcome to comment on the online version of the paper.  
1188Correspondence and requests for materials should be addressed to B.R.  
1189([biren@ucsd.edu](mailto:biren@ucsd.edu)) or I.J. ([ijung@kaist.ac.kr](mailto:ijung@kaist.ac.kr)). All raw and processed data  
1190have been deposited in the GEO database under accession number  
1191GSE86189.

1192

1193

## 1194 **Figure Legends**

### 1195 **Figure 1. Genome-wide mapping of promoter-centered chromatin** 1196 **interactions in diverse human tissues and cell types.**

1197 **a**, A schematic of the pcHi-C procedure. **b**, Barplots of normalized  
1198 promoter-centered chromatin interaction frequencies (y-axis) emanating  
1199 from the *ADAMTS1* promoter (translucent gray). The identified chromatin  
1200 interactions are shown below the axis (purple loops). Highlighted in  
1201 translucent yellow are cell/tissue type specific interactions. **c**, Barplots of  
1202 the number of chromatin interactions that span a given genomic distance  
1203 are shown. Orange line indicates the accumulated fraction of chromatin  
1204 interactions from all 27 tissues/cell types. **d**, Boxplots showing the fold  
1205 enrichment of the interaction frequencies between the active (colored  
1206 dots) or bivalent promoters (gray dots) and each chromatin state. The 17  
1207 chromatin states shown were obtained by processing 18-state ChromHMM  
1208 model after merging genic enhancer 1 and 2 annotations. KS-tests were  
1209 performed between interactions originating from active promoter regions  
1210 (colored dots) and those from bivalent promoters (gray dots) (\*\* p value <  
1211 0.01 and \*\*\* p value < 0.001). The chromatin states that interact more  
1212 frequently with active promoters than bivalent promoters were  
1213 highlighted in translucent yellow. The chromatin states that interact more  
1214 frequently with bivalent promoters than active promoters were  
1215 highlighted in translucent blue. Whiskers correspond to the highest and  
1216 lowest points within 1.5× the interquartile range.

1217

1218 **Figure 2. Inference of target genes of *cis*-regulatory sequences**  
1219 **from pHi-C data.**

1220 **a**, Illustrative LocusZoom plot of eQTLs for *VLDLR* (top) and pHi-C  
1221 interactions originating from the *VLDLR* promoter region in aorta tissue  
1222 (bottom). Dots along the LocusZoom plot represent the P-values of SNPs'  
1223 association with *VLDLR* gene expression levels in the aorta (data obtained  
1224 from GTEx). Dots are also color-coded based on their Linkage  
1225 Disequilibrium (LD) scores with a tagging SNP. The blue bars indicate the  
1226 recombination rate. **b**, Barplots showing fold enrichment between the  
1227 number of eQTL-associations matched to P-O pHi-C interactions and that  
1228 of distance matched random P-O pHi-C interactions for 12 corresponding  
1229 tissue types. P-O interactions in all 12 tissues were significantly enriched  
1230 for eQTL associations (empirical p value < 0.01). The dotted line indicates  
1231 the expected fold-enrichment (i.e. 1). Error bars indicate standard  
1232 deviation obtained by 1,000 random trials. **c**, An illustrative example of  
1233 tissue specifically expressed gene, showing positive correlation between  
1234 the chromatin state (H3K27ac) at a distal cRE and expression levels (RNA-  
1235 seq) of the promoter connected by long-range chromatin interactions. The  
1236 significant chromatin interaction between the *POU3F3* promoter and a  
1237 distal cRE marked by H3K27ac ~350kb upstream in hippocampus (HC)  
1238 tissue is shown at the top. Shown below are H3K27ac signals and  
1239 locations of genes. The bar plots at the lower half show the H3K27ac  
1240 signals at the distal cRE (left), the transcript levels of the *POU3F3*  
1241 (middle), and the normalized pHi-C interaction frequencies between the

1242 *POU3F3* promoter and the distal cRE (right). **d**, Boxplots illustrating the  
1243 H3K27ac signals after quantile normalization at the cREs exhibiting  
1244 hippocampus specific pHi-C interactions with putative target promoters.  
1245 These cREs are marked by higher levels of H3K27ac in hippocampus than  
1246 in other cell/tissues types (KS-test p value < 0.005). Whiskers correspond  
1247 to the highest and lowest points within 1.5× the interquartile range. **e**,  
1248 Boxplots showing transcript levels of the putative target genes predicted  
1249 by hippocampus specific pHi-C interactions. Genes are significantly  
1250 expressed in hippocampus compared to other cell/tissues types (KS-test p  
1251 value < 0.005) except dorsolateral prefrontal cortex (KS-test p value 0.27)  
1252 and mesenchymal stem cell (KS-test p value 0.02). Whiskers correspond  
1253 to the highest and lowest points within 1.5× the interquartile range. **f-h**,  
1254 Heatmaps demonstrate the enrichment of pHi-C interactions for  
1255 cell/tissue-specific cRE-promoter pairs (column) in the corresponding  
1256 cell/tissue type (row) (f), z-score transformed H3K27ac signals (column) at  
1257 the promoter associated cREs (row) (g), and z-score transformed FPKM  
1258 values (column) of RNA-seq at the cREs' putative target genes (row) (h).  
1259 Color indicates mean values of distance normalized pHi-C interaction  
1260 frequencies for H1 (n=5,096), MES (n=3,380), MSC (n=5,188), NPC  
1261 (n=1,295), TB (n=5,830), HC (7,100), FC (n=15,733), IMR90 (n=5,313),  
1262 LG (n=1,101), LI (n=2,656), PA (n=2,751), SB (n=1,072), TH (n=2,233),  
1263 GA (n=1,511), LV (n=1,501), PO (n=865), RV (n=1,049), SX (n=9,228),  
1264 AD (n=1,998), AO (n=4,407), and LCL (n=10,283) (f), z-score transformed  
1265 H3K27ac signals for H1 (n=5,813), MES (n=3,951), MSC (n=5,790), NPC

1266(n=1,631), TB (n=6,616), HC (7,712), FC (n=15,389), IMR90 (n=6,146),  
1267LG (n=1,345), LI (n=3,224), PA (n=3,211), SB (n=1,310), TH (n=2,717),  
1268GA (n=1,903), LV (n=1,741), PO (n=1,087), RV (n=1,296), SX (n=10,077),  
1269AD (n=2,342), AO (n=5,179), and LCL (n=10,945) (g), and z-score  
1270transformed FPKM values for H1 (n=1,589), MES (n=1,024), MSC  
1271(n=1,587), NPC (n=450), TB (n=1,920), HC (2,339), FC (n=4,830), IMR90  
1272(n=1,743), LG (n=310), LI (n=870), PA (n=845), SB (n=293), TH (n=747),  
1273GA (n=460), LV (n=368), PO (n=281), RV (n=295), SX (n=3,054), AD  
1274(n=550), AO (n=1,381), and LCL (n=3167) (h). KS-test was performed  
1275between pcHi-C interaction frequencies, z-score transformed H3K27ac  
1276signals, and z-score transformed FPKM values in the matched cell/tissue  
1277types (values in diagonal in each heatmap) and those in other cell/tissue  
1278types (values in off diagonal in each heatmap), demonstrating significant  
1279association of cRE-promoter pairs with cell/tissue-specific cRE H3K27ac  
1280signals and gene expression (KS-test p value < 2.2e-16).

1281

1282**Figure 3. Enhancer-like promoters involved in regulation of distal**  
1283**target genes.**

1284**a**, Browser snapshots of the *TMED4* locus showing H3K27ac signals and  
1285promoter-centered chromatin interactions. Shown at the RefSeq genes  
1286(top), H3K27ac histone modification signals as measured by ChIP-seq  
1287(middle) and promoter-centered chromatin interactions detected from  
1288pcHi-C experiments (bottom). Highlighted in translucent blue are  
1289promoter-promoter pairs showing highly correlated H3K27ac signal and

1290 significant pcHi-C interactions. Highlighted in gray is an adjacent promoter  
1291 of the *TMED4*. Shown below are Pearson correlation coefficient (PCC)  
1292 values based on H3K27ac signals and links based on pcHi-C interactions,  
1293 with MSC as the acronym for mesenchymal stem cell. **b**, Density plots  
1294 showing distributions of PCC values of H3K27ac (blue, median of  
1295 PCC=0.45, n=48,893), H3K4me1 (orange, median of PCC=0.67,  
1296 n=48,893), and H3K4me3 (green, median of PCC=0.64, n=48,893) signals  
1297 for P-P pcHi-C interactions. As a control, a density plot of PCC distributions  
1298 of H3K27ac signals for randomly selected promoter-promoter pairs is  
1299 shown (gray, median of PCC=0.02, n=48,142). X-axis indicates PCC of  
1300 histone modification signals between promoter-promoter pairs across 27  
1301 cell/tissue types. **c**, A pie chart showing the fraction of unique P-P  
1302 interactions matched by eQTL associations, of which 5.7% are P-P  
1303 interactions (n=1,976) in 12 matched tissue types (n=34,880). **d**, An  
1304 illustrative LocusZoom plot of eQTLs for *DACT3* gene expression in  
1305 dorsolateral prefrontal cortex. Both the *DACT3* gene promoter region and  
1306 the *AP2S1* gene promoter that contains significant eQTLs are highlighted  
1307 in translucent orange, dots along the LocusZoom plot represent SNPs, and  
1308 their significance of association with the *DACT3* gene expression is plotted  
1309 along the left y-axis. Dots are also color-coded based on their LD score  
1310 with a tag SNP (rs78730097). The blue line indicates the estimated  
1311 recombination rate, as plotted along the right y-axis. Gene expression  
1312 levels detected by RNA-seq and RefSeq genes are plotted below the  
1313 LocusZoom plot. **e**, Illustrative genome browser snapshot of RNA-seq

1314 results between control and mutant clones with deletion of the core  
1315 promoter regions of the *ARIH2OS*. In both control and mutant cells, the  
1316 *ARIH2OS* gene was not expressed, but the expression of the *NCKIPSD*  
1317 gene, which displays chromatin interactions with the *ARIH2OS* gene  
1318 promoter, was significantly down-regulated in the mutant clones (FDR  
1319 adjusted p value from cuffdiff = 0.02). **f**, Genome browser snapshot  
1320 showing the promoter containing an eQTL targeted by sgRNAs and its  
1321 distal target gene, *ABCF3*, together with H3K27ac and chromatin  
1322 accessibility (DNaseI). The relative mRNA expression levels of the *ABCF3*  
1323 quantified by RT-qPCR are shown below, which were significantly down-  
1324 regulated in both mutants (\*\*\*) one-tailed KS-test p value < 0.001). Error  
1325 bars indicate standard deviation of three mutant clones with technical  
1326 triplicates.

1327

**1328 Figure 4. Analysis of human diseases and physiological traits**  
**1329 based on the putative target genes of GWAS-SNPs.**

1330 **a**, Genome browser snapshot showing multiple cREs harboring GWAS-  
1331 SNPs and their common target gene, *NT5DC2*, together with signals of  
1332 H3K27ac (ChIP-seq) and chromatin accessibility (DNaseI). The DNA  
1333 fragments containing all these cREs interact with the *NT5DC2* gene  
1334 promoter region as evidenced by pHi-C analysis (arcs). The relative  
1335 mRNA expression levels of the *NT5DC2* upon induced mutation of GWAS-  
1336 SNPs with sgRNA were quantified by RT-qPCR as shown below. Error bars  
1337 indicate standard deviation of two mutant clones with technical triplicates

1338(KS-test, \*\* p value < 0.01, \*\*\* p value < 0.001). **b**, Hierarchical clustering  
1339of human diseases and traits based on similarities of the putative target  
1340genes of trait-associated SNPs and SNPs in LD. The color intensity of each  
1341dot indicates Pearson correlation coefficient (PCC) of the putative target  
1342genes between two diseases or traits. Color bars on the left and top  
1343demarcate the clusters. **c, d**, Shown are similarities, as measured by  
1344Pearson correlation coefficient (PCC), between traits in the same order as  
1345Fig. 4b, based on either the nearest genes of the GWAS SNPs (c) or the  
1346GWAS SNPs alone (d). The color intensity of each dot indicates PCC of  
1347target gene similarities between two traits. **e**, Hierarchical clustering of  
1348GO biological processes (each column, n=126) for the trait clusters  
1349defined in Fig. 4b (each row, n=40). Each entry indicates  $-\log_{10}(\text{p-value})$   
1350value of GO biological processes in the corresponding cluster. Several  
1351representative biological processes are highlighted.

1352

## 1353 **Extended Data Figure Legends**

### 1354 **Extended Data Figure 1. Capture Hi-C design, probe synthesis,** 1355 **and target enrichment workflow.**

1356 **a**, Schematic of probe design for Promoter Capture Hi-C experiments. For  
1357 each promoter (black rectangle), two flanking *HindIII* cut sites were  
1358 identified. A 15bp buffer was then added to each side of the *HindIII* cut  
1359 site, followed by allocation of three 120-mer capture probes to the same  
1360 sites, with a 30bp shift between the adjacent probes. In total, 12 capture  
1361 probes were designed for each promoter and all probes were targeted to  
1362 the Watson Strand. **b**, Schematic workflow of custom RNA probe  
1363 synthesis. Single stranded DNA (ssDNA) probe synthesis by CustomArray,  
1364 Inc., is shown from top to bottom; PCR amplification with SP6 recognition  
1365 sequence completion and purification, BsrDI digestion and purification, *in*  
1366 *vitro* transcription in the presence of biotinylated UTP and purification, and  
1367 pooling of probe batches using equal mass ratios. **c**, Schematic workflow  
1368 of target enrichment of Hi-C libraries (Promoter Capture Hi-C). From top to  
1369 bottom, preparation of library mix, hybridization buffer, and probe mix,  
1370 followed by combining the mixes and overnight incubation to bind probes  
1371 to Hi-C template. Then, preparation of streptavidin beads and wash  
1372 buffers, followed by binding of RNA:DNA duplexes to streptavidin beads  
1373 and rigorous washing to remove off-target binding. And lastly, PCR  
1374 amplification of the resulting Promoter Capture Hi-C library.

1375

1376 **Extended Data Figure 2. Overview of samples and capture probe**  
1377 **quality control.**

1378 **a**, Schematic overview of cell and tissue types analyzed by Promoter  
1379 Capture-Hi-C and note of other datasets available for these samples.  
1380 Embryonic or embryonic-derived cell types are on the left and tissues are  
1381 tabled on the right according to their developmental origin. **b**, Bar plots  
1382 showing the fraction of number of TSS in a DNA fragment. **c**, Scatter plot  
1383 showing the reproducibility of probe density from RNA-seq data between  
1384 two probe synthesis experiments. Each dot on the scatter plot represents  
1385 a single promoter and the value is the aggregated probe density from all  
1386 probes assigned to that given promoter. **d**, Venn diagram showing the  
1387 number of targeted regions that contain detectable probe density based  
1388 on RNA-seq of the capture probes from each replicate of probe synthesis.  
1389 **e**, Snapshot of Promoter Capture-Hi-C probe density from RNA-seq  
1390 analysis of the capture probes. Two replicates of probe synthesis and  
1391 subsequent RNA-seq are shown, followed by GENCODE gene annotations.  
1392 **f**, Zoomed-in snapshot of Promoter Capture Hi-C probe density from RNA-  
1393 seq analysis of the capture probes. Below the replicate RNA-seq datasets  
1394 are the *HindIII* cut sites and GENCODE gene annotations, illustrating that  
1395 the vast majority of probe density is only found around *HindIII* restriction  
1396 sites flanking promoters. **g, h**, Histograms of the probe densities  
1397 measured by RNA-seq (x-axis) in each promoter from replicate 1 (g) and  
1398 replicate 2 (h) of probe synthesis.

1399

1400**Extended Data Figure 3. General characterization of promoter-**  
1401**centered long-range interactions.**

1402**a**, Identified pHi-C chromatin interactions across multiple cell/tissue  
1403types are plotted in Genome Browser, with the darkness of blue  
1404corresponding to the strength of interactions. RefSeq genes are presented  
1405below the snapshot. **b**, Fraction of pHi-C interactions uniquely detected  
1406in one cell/tissue type (green) or also detected in other cell/tissue types  
1407(orange). The average fraction of cell/tissue-specific interactions is not  
1408over-estimated due to the number of tested samples (at 22 samples the  
1409fraction of cell/tissue-specific interactions reach plateau) and tissue-  
1410heterogeneity (similar trend was observed when we only considered pHi-  
1411C interactions obtained from cell lines). **c**, Snapshot of a locus showing  
1412promoter-centered long-range interactions from pHi-C data in H1-hESC  
1413(bottom, purple loops) in the context of TAD annotations (blue rectangles)  
1414identified from Hi-C data (top, red) in H1-hESC. RefSeq genes are shown  
1415at the bottom. **d**, Fraction of P-O pHi-C chromatin interactions in the  
1416context of TAD annotations with the respective cell/tissue types.

1417

1418**Extended Data Figure 4. Validation of Promoter Capture Hi-C**  
1419**Interactions.**

1420**a**, Browser snapshot of the *CCL* gene cluster, highlighting the similarity of  
1421promoter-centered interactions from Promoter Capture Hi-C and high  
1422resolution Hi-C data in IMR90. The top two tracks show histone  
1423modification signals for H3K4me3 and H3K27ac, followed by RefSeq

1424 genes. Below are pcHi-C chromatin in IMR90 (blue loops) and promoter-  
1425 centered chromatin interactions from high-resolution Hi-C data in IMR90  
1426 (reddish brown loops). **b-e**, ROC plots illustrating the prediction  
1427 performance of Promoter Capture Hi-C result for *in situ* Hi-C loops  
1428 anchored at promoters in lymphoblastoid (b), IMR90 (c), hippocampus (d),  
1429 and dorsolateral prefrontal cortex (e). Promoter centered interactions for  
1430 *in situ* Hi-C loops were considered as true interactions, and ROC plots  
1431 were drawn for the corresponding pcHi-C result. ROC scores are shown in  
1432 the ROC plot. **f**, ROC plots showing the reproducibility of pcHi-C chromatin  
1433 interactions between biological replicates. pcHi-C interactions from one  
1434 replicate were used as true interactions, and ROC plots were drawn for the  
1435 other replicate. **g-k**. Venn diagrams presenting the number of commonly  
1436 identified pcHi-C interactions between biological replicates for  
1437 lymphoblastoid (g), dorsolateral prefrontal cortex (h), mesenchymal stem  
1438 cell (i), lymphoblastoid processed by CHICAGO (j), and GM12878 with  
1439 previously published pcHi-C data<sup>18</sup> (k). Hypergeometric p-values are  
1440 shown together. **l-m**, Illustration of interaction intensity in the replicates  
1441 of lymphoblastoid (l) and mesenchymal stem cells (m), depending on the  
1442 replicate consistency. Whiskers correspond to the highest and lowest  
1443 points within 1.5× the interquartile range.

1444

1445 **Extended Data Figure 5. Integrative analysis of long-range**  
1446 **chromatin interactions with epigenome.**

1447**a, b**, Shown are histograms of number of interacting cREs per promoter  
1448(a) and number of interacting promoters per cRE (b). Y-axis indicates  
1449frequency of the corresponding value in x-axis. **c**, Depiction of identified  
1450long-range promoter-centered interactions across a 0.84Mb locus in  
1451lymphoblastoid (top). Shown below are histone modification signals  
1452obtained from ChIP-seq analyses<sup>35</sup>, as well as accessible chromatin  
1453regions measured from DNaseI hypersensitivity assay. **d**, Depiction of  
1454extensively interacting DNA fragments (EIF) from P-P and P-O interactions,  
1455and transcription factor (TF) binding clusters identified in GM12878 cells  
1456for the same region shown in Extended Data Fig. 5c. Below are 67 TF  
1457binding profiles obtained from TF ChIP-seq results performed in GM12878  
1458cells. Highlighted in translucent blue are overlapping EIF and TF binding  
1459clusters. EIF was defined in each cell/tissue type by selecting frequently  
1460interacting DNA fragments with multiple promoters in terms of 0.01  
1461Poisson p value cutoff. **e, f**, Bar plots showing the number of P-O EIF  
1462overlapping with TF clusters compared to random expectation in  
1463lymphoblastoid (e) and H1-hESC (f). Error bars indicate standard deviation  
1464of expectation values calculated by using typical TF peaked regions (blue)  
1465and generating random genomic regions (green). Empirical p-value shows  
1466statistical significance (\*\*\*) p value < 0.001). **g, h**, Bar plots showing the  
1467number of P-P EIF overlapping with TF clusters compared to random  
1468expectation in lymphoblastoid (g) and H1-hESC (h). Error bars indicate  
1469standard deviation of expectation values calculated by using typical TF  
1470peaked regions (blue) and generating random genomic regions (green).

1471 Empirical p-value shows statistical significance (\*\*\*) p value < 0.001). **i**, An  
1472 array of bar plots showing the number of P-O EIF overlapping with super-  
1473 enhancers (first bar plot, orange), compared to typical enhancers (middle  
1474 bar plot, blue) and random genomic regions (last bar plot, purple). Error  
1475 bars indicate standard deviation of expectation values obtained by 10,000  
1476 permutations. Empirical p-value showed statistical significance for all  
1477 tested cell/tissue types compared to random genomic regions (p value <  
1478 0.0001).

1479

1480 **Extended Data Figure 6. Enrichment of long-range chromatin**  
1481 **interactions at various chromatin states generated by a 50-state**  
1482 **ChromHMM model.**

1483 **a**, Boxplots showing the fold change of interaction frequencies between  
1484 active/bivalent promoters and each chromatin state over expected values.  
1485 The 50 chromatin states (E01-E50) were obtained from the 50-state  
1486 ChromHMM model. KS-tests were performed between active promoters  
1487 and bivalent promoters (two adjacent boxplots) (\*\* p value < 0.01 and \*\*\*  
1488 p value < 0.001). The chromatin states that interact more frequently with  
1489 active promoters than bivalent promoters were highlighted in pink  
1490 asterisk. The chromatin states that interact more frequently with bivalent  
1491 promoters than active promoters were highlighted in blue asterisk.  
1492 Whiskers correspond to the highest and lowest points within 1.5× the  
1493 interquartile range. **b**, A heatmap showing an emission parameter matrix  
1494 of each chromatin state in which each row corresponds to a different

1495chromatin state and each column corresponds to an emission probability  
1496of a chromatin mark shown at the top. The pre-calculated emission  
1497parameter heatmap was downloaded from the 50-state ChromHMM model  
1498established by Roadmap Epigenomics Project.

1499

**1500Extended Data Figure 7. Validation of P-O interactions with eQTL  
1501associations.**

1502**a-c**, Illustrative LocusZoom plots of eQTLs for the *HS3ST1* (a), the  
1503*METTL25* (b), and the *DAAM1* (c) gene expression in left ventricle,  
1504dorsolateral prefrontal cortex, and aorta, respectively. RefSeq genes are  
1505plotted below the LocusZoom plot. Identified pHi-C interactions are  
1506shown as loops (purple) in the bottom. **d**, Array of bar plots showing the  
1507number of matched eQTL associations between P-O pHi-C chromatin  
1508interactions after exclusion of DNA fragment shared promoters and  
1509random expectation across 14 matched tissue types from GTEx database.  
1510All P-O pHi-C interactions are significantly enriched by eQTL associations  
1511compared to random P-O pHi-C interactions with or without distance  
1512match (\* empirical p-value <0.05, \*\* empirical p-value <0.01, \*\*\*  
1513empirical p-value <0.001). Error bars indicate standard deviation of  
1514random expectation values. **e**, Density plots showing the number of  
1515unique eQTLs per P-O pHi-C interaction fragment and randomized  
1516interactions. No significant difference between pHi-C interactions and  
1517randomized interactions (KS-test p value > 0.05) except pancreas (p value  
1518= 0.02), gastric (p value = 0.009), and lung (p value = 0.03). **f**, Shown are

1519 boxplots of the distribution of PCC between H3K27ac signals in cRE-  
1520 promoter pairs connected by pHi-C interactions after exclusion of  
1521 multiple fragment spanning cREs (Orange, n=154,055), compared to the  
1522 distribution of random expectation with matched distance (dark gray,  
1523 n=154,055) and without matched distance (gray, n=154,055). We only  
1524 considered P-O pairs where other DNA fragments are marked by H3K27ac  
1525 peaks in at least one cell/tissue type analyzed. We also excluded two  
1526 fragments spanning cREs. KS-test was performed between P-O pairs and  
1527 random control, demonstrating that P-O pairs showed significant positive  
1528 correlation (\*\*\*) Welch's t-test p value < 2.2e-16). Whiskers correspond to  
1529 the highest and lowest points within 1.5× the interquartile range. **g**,  
1530 Similar to Extended Data Fig. 7e, but the distribution of PCC between  
1531 H3K27ac signals at a cRE and target gene expressions of the cRE  
1532 connected by pHi-C interactions. KS-test was performed between P-O  
1533 pairs (orange, n=154,055), distance matched random control (dark gray,  
1534 n=154,055), and random control (gray, n=154,055), revealing that P-O  
1535 pairs showed significant positive correlation (\*\*\*) Welch's t-test p value <  
1536 2.2e-16). Whiskers correspond to the highest and lowest points within  
1537 1.5× the interquartile range.

1538

1539 **Extended Data Figure 8. Functional analysis of promoter-**  
1540 **promoter interactions.**

1541 **a**, Pie chart showing the fraction of promoter-promoter interactions (P-P)  
1542 among all pHi-C interactions. The fraction of P-P pHi-C interactions

1543 modestly decrease to 6.5% after excluding fragment that harbor multiple  
 1544 promoters. **b**, An array of bar plots showing the number of eQTL  
 1545 associations matched to P-P pcHi-C interactions (left, purple), compared to  
 1546 random expectation with matched distance (middle, blue) and without  
 1547 matched distance (right, light blue). Each bar plot represents analysis of a  
 1548 different tissue. Error bars indicate standard deviation of random  
 1549 expectation values. Empirical p values are shown at the top (\* < 0.05, \*\*  
 1550 < 0.01, \*\*\* < 0.001). **c**, **d**, Illustrative LocusZoom plots of *FHOD1* eQTLs  
 1551 (c) and *POFUT2* eQTLs (d) in left ventricle and aorta, respectively.  
 1552 Promoters that contain significant eQTLs and target promoters are  
 1553 highlighted in translucent orange. Dots along the LocusZoom plot  
 1554 represent SNPs, and their significance of association with *FHOD1* and  
 1555 *POFUT2* gene expression is plotted along the left y-axis, respectively. The  
 1556 blue line traveling across the scatterplot indicates the estimated  
 1557 recombination rate, as plotted along the right y-axis. RefSeq genes and  
 1558 RNA-seq are plotted below the LocusZoom plot. pcHi-C interactions are  
 1559 shown as purple in the bottom. **e**, Bar plot showing the eQTL associations  
 1560 between the SNP rs78730097 and surrounding genes, showing the most  
 1561 significant association with the distal gene *DACT3*. Y-axis indicates -  
 1562  $\log_{10}$ (eQTL association p value). **f**, **g**, Bar plots showing FPKM values of  
 1563 distal target gene expressions upon deletion of core promoter regions of  
 1564 the *ARIH2OS* (f) and the *ZNF891* (g). Two biological replicates of one  
 1565 mutant clone for the *NCKIPSD* and two biological replicates of three  
 1566 mutant clones for the *ZNF84* were measured using RNA-seq, respectively.

1567 FDR-adjusted p value obtained from cuffdiff is shown together. N.S  
1568 indicates statistically non-significant. **h**, Bar plots showing FPKM values of  
1569 two nearby genes of the *ARIH2OS* and one nearest gene of the *NCKIPSD*  
1570 (y-axis) upon deletion of core promoter regions of the *ARIH2OS*. The  
1571 *ARIH2*, a DNA fragment sharing gene with the *ARIH2OS*, is excluded. FDR-  
1572 adjusted p value obtained from cuffdiff is shown together. Corresponding  
1573 gene name is shown on the top of bar plots. **i**, The relative mRNA  
1574 expression levels of distal target genes (orange) and nearby genes (gray)  
1575 of promoter-proximal eQTLs quantified by RT-qPCR are shown. Error bars  
1576 indicate standard deviation from total six mutant clones for two separate  
1577 sgRNAs with technical triplicates. One-sided KS-test p values are shown  
1578 together on the top of each bar plot (\*\*\*) p value < 0.001).

1579

1580 **Extended Data Figure 9. Identification of target genes of disease-**  
1581 **associated genetic variants.**

1582 **a**, Illustration of the strategy to identify target genes of each GWAS trait.  
1583 An example result is shown for Alzheimer disease. Both known and novel  
1584 target genes were identified according to literature search. **b**, Venn  
1585 diagram showing number of target genes by pHi-C interactions and by  
1586 nearby gene information for the GWAS-SNPs associated with Parkinson  
1587 disease. **c**, Number of matched disease-associated genes in each group of  
1588 target genes identified in Parkinson disease. **d**, Fraction of distal genes  
1589 (blue) and nearby genes (gray) among the identified target genes of  
1590 GWAS-SNPs based on pHi-C interactions (left). Expected fraction is shown

1591by calculating the fraction of nearby genes when we consider a nearest  
1592gene over 15kb as a GWAS-SNP target gene (right). **e**, Barplot showing  
1593the relative mRNA expression levels of *GNL3* upon induced mutation of  
1594GWAS-SNPs with sgRNA as quantified by RT-qPCR as a control. Error bars  
1595indicate standard deviation of two mutant clones with technical triplicates.  
1596**f**, Barplot showing RT-qPCR results of relative target gene expression (y-  
1597axis) between mutant and control. Error bars indicate standard deviation  
1598of two mutant clones with technical triplicates. The mutants showing  
1599significant down regulation of target genes are shown in orange (KS-test,  
1600\*\* p value < 0.01, \*\*\* p value < 0.001). sgRNA target GWAS-SNP genomic  
1601coordinate, rsID, associated disease, distal target gene information, high  
1602LD SNP on coding region, and related publication PMID information are  
1603shown together.

1604

1605**Extended Data Figure 10. Analysis of disease-disease**  
1606**associations.**

1607**a**, Illustration of the strategy to calculate the similarity between GWAS  
1608mapped traits using target gene similarity information. **b**, **c**, Shown are  
1609similarities, as measured by Pearson correlation coefficient (PCC),  
1610between traits in the same order as Fig. 4b based on similarities of the  
1611putative GWAS-SNP target genes without shared promoters (b) and  
1612without genes located in HLA and HIST locus (c). The color intensity of  
1613each dot indicates Pearson correlation coefficient (PCC) of the putative  
1614target genes between two diseases or traits. **d**, Shown are similarities, as

1615 measured by Pearson correlation coefficient (PCC), between traits based  
1616 on the 5 nearest genes of the GWAS SNPs. The color intensity of each dot  
1617 indicates PCC of target gene similarities between GWAS mapped traits. **e,**  
1618 Bar plots showing the fraction of number of TSS in a DNA fragment  
1619 between all TSS and TSS corresponding genes in cluster 38 of Fig. 4b.

1620

1621

1622 **Supplementary Tables**

1623

1624 **Supplementary Table 1. List of cell/tissue types analyzed in this**  
1625 **study**

1626 **Supplementary Table 2. Number of processed pcHi-C reads**

1627 **Supplementary Table 3. List of P-O interactions**

1628 **Supplementary Table 4. List of P-P interactions**

1629 **Supplementary Table 5. Number of significant pcHi-C promoter-**  
1630 **centered interactions**

1631 **Supplementary Table 6. The list of mean and median distance of**  
1632 **pcHi-C and eQTL associations in each cell/tissue type**

1633 **Supplementary Table 7. The numbers and fractions of overlapped**  
1634 **interactions between replicates**

1635 **Supplementary Table 8. Total number of extensively interacting**  
1636 **DNA fragments (Poisson P value < 0.01)**

1637 **Supplementary Table 9. List of TF ChIP-seq data used to define**  
1638 **GM12878 TF clusters**

1639 **Supplementary Table 10. List of TF ChIP-seq data used to define**  
1640 **H1-hESC TF clusters**

1641 **Supplementary Table 11. Summary of matched eQTL-associations**  
1642 **with P-O pcHi-C interactions**

1643 **Supplementary Table 12. List of P-O pcHi-C interactions and**  
1644 **matched eQTL relationships**

1645 **Supplementary Table 13. Summary of matched eQTL-associations**  
1646 **with P-P pcHi-C interactions**

1647 **Supplementary Table 14. List of P-P pcHi-C interactions and**  
1648 **matched eQTL relationships**

1649 **Supplementary Table 15. Summary of average number of target**  
1650 **genes of GWAS-SNPs**

1651 **Supplementary Table 16. List of putative target genes of GWAS-**  
1652 **SNPs**

1653 **Supplementary Table 17. List of GWAS mapped traits and**  
1654 **enriched GO biological processes in Fig. 4b**

1655 **Supplementary Table 18. Enriched pathway analysis of Cluster 38**  
1656 **in Fig. 4b**